fhoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche finance report finance report finance brief key results sales core operating profit margin cer growth sales pharmaceuticals diagnostics group change sales mchf mchf chf cer ifrs results sales operating profit net income net income attributable roche shareholders diluted eps chf dividend per share chf core results research development core operating profit core eps chf free cash flow operating free cash flow free cash flow change mchf mchf chf cer net debt capitalisation debt equity proposed board directors cer constant exchange rates percentage changes constant exchange rates calculated using simulations reconsolidating results constant exchange rates average rates year ended december core results core eps earnings per share exclude noncore items global restructuring plans amortisation impairment goodwill intangible assets allows transparent assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core concept fully described pages reconciliations ifrs core results given therefinance brief roche roche group reported solid overall results sales grew constant exchange rates cer core earnings per share also increased excluding impact double charge million swiss francs related us branded prescription drug fee underlying earnings grew sales group sales increased cer billion swiss francs growth swiss franc terms pharmaceuticals sales growth cer continued growth franchise avastin oncology portfolio well tamiflu actemraroactemra xolair sales xeloda pegasys decreased diagnostics sales showed growth cer professional diagnostics major contributor operating results core operating profit increased cer billion swiss francs decline swiss franc terms excluding double charge us branded prescription drug fee underlying operating profit grew research development expenditure grew cer billion swiss francs core basis focus oncology neuroscience immunology therapeutic areas research development costs group sales ifrs operating results include noncore expenses billion swiss francs includes billion swiss francs amortisation impairment goodwill intangible assets well billion swiss francs global restructuring plans business combinations nonoperating results core net financial expenses decreased billion swiss francs billion swiss francs driven income divestments equity securities lower interest expenses ifrs net financial expenses additionally includes loss billion swiss francs noncore major debt restructuring net income ifrs net income decreased cer billion swiss francs decline swiss franc terms due higher impairments goodwill intangible assets higher global restructuring charges including base effect income billion swiss francs reversal impairment charges results core earnings per share increased cer swiss francs terms excluding impact double charge us branded prescription drug fee underlying earnings grew cash flows operating free cash flow billion swiss francs decrease cer underlying growth operating business offset higher capital expenditure free cash flow increased cer billion swiss francs driven sales equity securities lower interest payments mergers acquisitions notably intermune acquisition utilised billion swiss francs cash billion us dollars financed new debt issuances repayment debt ahead schedule notes bonds issued finance genentech transaction repaid end financial position net working capital increased cer due higher levels inventories intermune inventory fair value adjustment launches growth key products higher safety stock levels increased demand key markets net debt increased billion swiss francs billion swiss francs mainly due intermune acquisition net debt percentage total assets credit ratings strong moodys standard poors aa shareholder return dividends proposal made increase dividends swiss francs per share represent th consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr representing combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles current liabilities operating segment information provisions contingent liabilities net financial expense debt income taxes equity attributable roche shareholders business combinations chugai global restructuring plans noncontrolling interests property plant equipment employee benefits goodwill pensions postemployment benefits intangible assets equity compensation plans inventories earnings per share nonvoting equity security accounts receivable statement cash flows marketable securities risk management cash cash equivalents related parties noncurrent assets subsidiaries associates current assets significant accounting policies accounts payable subsequent events noncurrent liabilities report roche management internal control financial reporting report statutory auditor consolidated financial statements report independent auditor internal control financial reporting multiyear overview supplementary information roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings report statutory auditor financial statements financial review roche group financial review roche group results sales billions chf core operating profit billions chf cer growth sales net income attributable roche shareholders billions chf core eps chf roche groups results showed growth core operating activities sales core operating profit constant exchange rates sales increased driven oncology portfolio especially medicines herpositive breast cancer professional diagnostics business core operating profit grew rate sales increase due double charge million swiss francs related us branded prescription drug fee solid operating performance combined higher income sales equity securities lower financing costs lead increase core eps constant exchange rates excluding double charge underlying earnings grew operating free cash flow billion swiss francs sales sales pharmaceuticals division rose billion swiss francs driven oncology portfolio especially franchise grew also strong demand actemraroactemra xolair sales increasing respectively sales xeloda lower offpatent us europe regional growth significant us europe latin america diagnostics sales grew consolidating divisions leading market position major growth area professional diagnostics sales diabetes care increased slightly core operating profit increased pharmaceuticals division growing diagnostics division profit pharmaceuticals grew due good sales growth marketing distribution costs included launch rollout new products notably newly acquired product esbriet investments emerging markets well increasing patient access medicines research development continued investments oncology neuroscience immunology therapeutic areas july us internal revenue service irs issued final regulations related branded prescription drug fee fundamentally changed key assumption triggering event liability recognition result onetime double charge operating profit impact million swiss francs diagnostics core operating profit grew due sales growth offset base effect pension plan changes excluding double charge groups core operating profit grew operating free cash flow billion swiss francs decrease strong cash generation underlying operations offset higher capital investments manufacturing facilities site development projects free cash flow increased constant exchange rates billion swiss francs driven sales equity securities lower interest tax payments offset higher annual dividend payments roche finance report roche group financial review group continued implementation several major global restructuring plans initiated prior years notably programme address longterm profitability diabetes care business diagnostics division total costs groups restructuring activities billion swiss francs impairment charges billion swiss francs recorded goodwill intangible assets mainly tissue diagnostics business major debt restructuring refinance groups longterm debt resulted loss billion swiss francs negative factors combined base effect income billion swiss francs reversal impairment charges results total turned increase core net income decrease net income ifrs basis comparing average exchange rates average exchange rates swiss franc stronger many major currencies particular japanese yen us dollar euro major latin american currencies overall impact strongly negative results expressed swiss francs compared constant exchange rates percentage point impact sales core operating profit core eps january swiss national bank snb announced discontinuing minimum exchange rate swiss francs per euro consequence stock markets switzerland fell significantly value swiss franc increased dramatically roche group fundamental impact foreseen example group incurs less overall costs switzerland token key markets us europe japan complete value chains meaning costs incurred local currencies swiss francs amounts reported financial report reflect changes exchange rates december since group uses swiss franc presentation currency consolidated financial statements weakening foreign currencies swiss franc negative currency translation impact groups consolidated results reported swiss francs currency translation sensitivity groups results movements foreign currency exchange rates included pages roche finance report financial review roche group income statement change change mchf mchf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests eps basic chf eps diluted chf core results sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core eps basic chf core eps diluted chf roche finance report roche group financial review sales sales increased constant exchange rates swiss francs us dollars billion swiss francs sales pharmaceuticals division rose billion swiss francs driven strong growth franchise well avastin tamiflu actemraroactemra xolair mabtherarituxan sales grew regions particularly us franchise grew xeloda pegasys sales declined xeloda offpatent us europe subject generic competition markets pegasys subject increased competition new therapies diagnostics division recorded sales billion swiss francs increase constant exchange rates consolidating leading market position major growth area professional diagnostics represents half divisions sales grew led immunodiagnostics business diabetes care sales increased despite continued us reimbursement cuts pricing pressure divisional operating results pharmaceuticals diagnostics corporate group mchf mchf mchf mchf sales core operating profit margin sales operating profit margin sales operating free cash flow margin sales divisional operating results development results compared pharmaceuticals diagnostics corporate group sales increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operating free cash flow increase cer margin percentage point increase core operating results currency translation significant impact operating results negative effect percentage points development group pharmaceuticals division core operating margins negative effect percentage points core operating margin diagnostics division pharmaceuticals division division increased core operating profit constant exchange rates driven sales growth continued marketing activities new products emerging markets including patient access programmes research development costs increased focus oncology neuroscience immunology therapeutic areas general administration costs increased due us branded prescription drug fee double charge base effect income changes groups pension plans results additional oneoff income divestment filgrastim franchise rights excluding double charge divisions core operating profit grew diagnostics division core operating profit driven sales growth operating profit negatively impacted base effect pension plan changes also negative impact cost sales development base effect vat refund million swiss francs excluding factors core operating profit grew ahead sales due contained marketing distribution research development costs division continued implementation global restructuring plans diabetes care business also continued implementation various projects roche finance report financial review roche group mergers acquisitions roche group completed acquisition several companies total cost acquired assets billion swiss francs cash billion swiss francs fair value contingent consideration arrangements september pharmaceuticals division acquired controlling interest intermune billion swiss francs acquisition adds new medicine idiopathic lung fibrosis esbriet roche portfolio esbriet sales million swiss francs recorded three months following intermune acquisition net negative impact million swiss francs core operating profit due postacquisition operating expenses intermune notably esbriet launch costs group issued billion us dollars debt finance transaction pharmaceuticals division also completed acquisitions seragon pharmaceuticals santaris pharma diagnostics division completed acquisitions genia technologies bina technologies sequencing business iquum molecular diagnostics business ariosa diagnostics acquisition closed january trophos acquisition expected close first quarter transaction foundation medicine expected close second quarter details given notes consolidated financial statements global restructuring plans group continued implementation several major global restructuring plans initiated prior years notably programme address longterm profitability diabetes care businesses diagnostics division total costs million swiss francs considerably higher costs totalled million swiss francs due results including income million swiss francs reversal previously incurred impairment charges bulk drug production unit vacaville site california global restructuring plans costs incurred millions chf diagnostics site consolidation plans total global restructuring costs employeerelated costs site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs split plans table reformatted prior years reflect relative development various plans includes diabetes care autonomy speed restructuring plan includes closure nutley site associated infrastructure environmental remediation costs includes plans pharmaceuticals division research development strategic realignment intermune integration specialty care field force europe diagnostics division september roche diabetes care announced autonomy speed initiative enable business focus diabetes care specific requirements speed processes decisionmaking drive efficiencies total costs million swiss francs incurred mainly employeerelated costs consultancy costs spending smaller plans within division million swiss francs included costs related projects restructuring former applied science business site consolidation operational closure us site nutley new jersey completed schedule end group currently process divesting site work remediating nutley site continuing significant additional restructuring expenses incurred site consolidation costs include related closure toluca mexico pharmaceuticals graz austria diagnostics sites roche finance report roche group financial review global restructuring plans total costs million swiss francs one major item impairment goodwill arising marcadia acquisition million swiss francs following exit cardiovascular metabolic diseases significant costs included million swiss francs relating field force reductions across europe pharmaceuticals divisions specialty care unit intermune integration costs million swiss francs costs million swiss francs arose implementation global outsourcing clinical trial monitoring pharmaceuticals division remaining minor plans totalled million swiss francs impairment goodwill intangible assets total impairment charges recorded goodwill intangible assets million swiss francs compared million swiss francs major part tissue diagnostics business impairment charges million swiss francs goodwill million swiss francs product intangible assets impairment product intangible assets represents reassessment latestage product development returned predesign phase demonstrate feasibility quality improvement impairment goodwill reflects decrease forecasted cash flows following reassessment combined reduced revenue expectations us following additional reimbursement cuts change discount rate used impairment testing mentioned goodwill impairment pharmaceuticals division million swiss francs included global restructuring plans addition pharmaceuticals division also recorded goodwill impairment charges million swiss francs related certain previous acquisitions also impairment charges divisions totalling million swiss francs resulting mainly decisions stop development various compounds details given notes consolidated financial statements pensions postemployment benefits disclosed financial report base effect operating income million swiss francs past service costs changes groups pension plans switzerland united kingdom germany amount million swiss francs recorded pharmaceuticals division million swiss francs diagnostics division remaining million swiss francs income allocated corporate mainly attributable previously divested businesses details given note consolidated financial statements legal environmental settlements march italian antitrust authority agcm issued verdict alleges roche novartis colluded artificially differentiate avastin lucentis order foster sales lucentis italy agcm fined roche million euros novartis million euros december administrative tribunal lazio upheld decision agcm roche strongly disagrees verdict appeal july roche paid fine protest avoid additional penalty fees prior appeal hearing recorded provision amount consolidated financial statements corresponding expense million swiss francs within general administration fine related interest reimbursed roche wins case details given note consolidated financial statements major debt restructuring result low interest rates capital markets group decided november restructure part debt consisted refinancing billion us dollars notes coupons originally due issuance billion us dollars notes due coupons major debt restructuring resulted loss repurchase million swiss francs details given note consolidated financial statements roche finance report financial review roche group treasury taxation core financing costs billion swiss francs decrease constant exchange rates interest expenses amortisation debt discounts issue costs lower debt repaid financial income included million swiss francs income equity securities notably gain million swiss francs sale equity security position late core tax expenses increased billion swiss francs groups effective core tax rate increased compared mainly due higher percentage core profit contribution coming tax jurisdictions relatively higher local tax rates average group tax rate notably us addition effective tax rate favourably impacted retrospective reenactment us research development tax credits january means results included two years credits respect net income earnings per share net income diluted eps decreased respectively constant exchange rates driven costs groups restructuring activities billion swiss francs impairment charges billion swiss francs combined base effect income billion swiss francs reversal impairment charges results contrast core net income core eps increased respectively core basis excludes noncore items global restructuring costs amortisation impairment goodwill intangible assets loss major debt restructuring excluding impact double charge million swiss francs related us branded prescription drug fee underlying earnings grew supplementary net income eps information given pages includes calculations core eps reconciles core results groups published ifrs results financial position financial position change change mchf mchf chf cer pharmaceuticals net working capital longterm net operating assets diagnostics net working capital longterm net operating assets corporate net working capital longterm net operating assets net operating assets net debt pensions income taxes nonoperating assets net total net assets compared start swiss franc strengthened japanese yen russian rouble euro resulting overall negative translation impact end balance sheet positions group level weakening swiss franc us dollar year led positive translation impact net operating assets offset group level natural hedge groups us dollardenominated debt exchange rates used given pages impacts changes exchange rates december reflected numbers see also note consolidated financial statements roche finance report roche group financial review pharmaceuticals division net working capital increased constant exchange rates trade receivables decreased despite higher sales strong collections forfaiting activities decreased payment terms addition inventory fair value adjustment resulting intermune acquisition underlying inventory levels increased ensure patient supply given increasing demand established products expanding markets addition new approvals recently launched products actemraroactemra subcutaneous formulation kadcyla trade payables increased result improving payment terms suppliers longterm net operating assets increased significantly due goodwill intangible assets billion swiss francs intermune acquisitions property plant equipment also increased due site development projects manufacturing facilities diagnostics decrease net working capital driven increase payables accrued liabilities higher trade payables partially offset higher inventories due higher demand emerging markets trade receivables increased driven stronger sales partially offset improved collections southern european countries longterm net operating assets decreased impairments tissue diagnostics business offset increase goodwill intangible assets genia bina iquum acquisitions increase net debt driven cash outflow acquisition intermune net pension liabilities increased billion swiss francs due lower interest rates increasing discounted defined benefit obligation yearend net tax position decreased mainly due deferred tax effects acquisition accounting increased net pension liabilities free cash flow free cash flow change change mchf mchf chf cer pharmaceuticals diagnostics corporate operating free cash flow treasury activities taxes paid dividends paid free cash flow groups operating free cash flow billion swiss francs decrease increase core operating profit offset higher capital expenditure increased inventories higher restructuring costs free cash flow increased constant exchange rates billion swiss francs driven sales equity securities lower interest payments lower tax payments offset higher annual dividend payments roche finance report financial review roche group pharmaceuticals division operating results pharmaceuticals division operating results change change mchf mchf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results core eps sales overview pharmaceuticals division sales therapeutic area change sales sales therapeutic area mchf mchf cer oncology immunology infectious diseases ophthalmology neuroscience therapeutic areas total sales pharmaceuticals division sales increased constant exchange rates growth driven oncology portfolio especially breast cancer franchise sales growth driven mainly following key products perjeta herceptin avastin kadcyla actemraroactemra mabtherarituxan products represent portfolio together contributed billion swiss francs constant exchange rates sales growth sales xeloda lower offpatent key markets subject generic competition pegasys sales lower due increased competition xolair grew tamiflu sales increased mainly due severe influenza season us sales valcytecymevene continued grow expected entry generic competition delayed roche finance report roche group financial review oncology franchise benefited continued strong demand perjeta us europe increased use combination herceptin also one growth drivers herceptin uptake kadcyla also strong us europe avastin showed strong growth across regions strong demand key indications several new approvals mabtherarituxan grew strongly europe region sales immunology increased due strong demand regions actemra roactemra monotherapy rheumatoid arthritis growth ophthalmology lucentis sales us increased largely due higher adoption treating diabetic macular edema dme product sales pharmaceuticals division sales change sales sales mchf mchf cer oncology avastin herceptin mabtherarituxan tarceva perjeta xeloda kadcyla zelboraf others total oncology immunology mabtherarituxan actemraroactemra xolair cellcept pulmozyme others total immunology infectious diseases pegasys tamiflu valcytecymevene rocephin others total infectious diseases ophthalmology lucentis total ophthalmology neuroscience madopar others total neuroscience therapeutic areas activasetnkase neorecormonepogin mircera nutropin others total therapeutic areas total sales total mabtherarituxan sales million swiss francs million swiss francs split oncology immunology franchises roche finance report financial review roche group mabtherarituxan nonhodgkins lymphoma nhl chronic lymphocytic leukemia cll follicular lymphoma fl rheumatoid arthritis ra well granulomatosis polyangiitis gpa microscopic polyangiitis mpa sales growth resulted increased use oncology rheumatoid arthritis indications sales oncology franchise stable due competitor products ra franchise sales grew increased share shorter dosing intervals subcutaneous formulation mabtherarituxan nhl approved europe australia russia chile mabtherarituxan regional sales change sales sales mchf mchf cer united states europe japan international total sales us sales stable results benefiting release sales reserves b program excluding base impact million swiss francs us sales rose sales showed strong growth europe sales driven increased market share fl firstline treatment cll sales also benefited decrease mandatory rebates germany international markets sales declined due economic conditions fourth quarter russia franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer overall growth franchise herceptin sales strong perjeta kadcyla grew strongly global rollout continues herceptin regional sales change sales sales mchf mchf cer united states europe japan international total sales perjeta regional sales change sales sales mchf mchf cer united states europe japan international total sales kadcyla regional sales change sales sales mchf mchf cer united states europe japan international total sales roche finance report roche group financial review herceptin sales grew us base results benefiting release sales reserves b program excluding impact million swiss francs us sales rose us growth resulted increased usage treatment breast cancer combination perjeta europe sales also increased good uptake herceptin subcutaneous formulation available many markets sales japan grew due increased usage combination perjeta international region grew subregions growth latin america resulted higher demand public sector sales asiapacific grew result improving patient access perjeta sales grew regions treating metastatic breast cancer significantly us europe uptake strongest germany france us growth also benefited use presurgical setting kadcyla sales grew regions strong uptake us europe addition good initial uptake japan avastin advanced colorectal breast lung kidney cervical ovarian cancer relapsed glioblastoma type brain tumour demand strong sales growing regions avastin regional sales change sales sales mchf mchf cer united states europe japan international total sales us sales increased driven growing demand colorectal cervical ovarian cancer treatment base results also benefited release sales reserves b program excluding impact million swiss francs us sales rose europe sales grew result increasing demand ovarian cancer indications japan sales increased strong demand treatment breast cancer well ovarian cancer malignant glioma international region growth driven launches ovarian cancer uptake colorectal cancer lucentis wet agerelated macular degeneration amd macular edema following retinal vein occlusion rvo diabetic macular edema dme lucentis regional sales change sales sales mchf mchf cer united states total sales us sales grew driven largely increased adoption lucentis treating dme actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis growth regions driven strong demand monotherapy earlier use rheumatoid arthritis actemraroactemra regional sales change sales sales mchf mchf cer united states europe japan international total sales demand particularly strong us europe sales also grew strongly japan significant uptake new subcutaneous formulation roche finance report financial review roche group tarceva advanced nonsmall cell lung nsclc pancreatic cancer tarceva regional sales change sales sales mchf mchf cer united states europe japan international total sales sales lower globally growth us japan offset declining sales europe international region due increasing impact competitor products pegasys hepatitis b c pegasys regional sales change sales sales mchf mchf cer united states europe japan international total sales sales decreased mainly us europe due increased competition new generation hepatitis c therapies international region growth latin america due public sector sales offset lower sales eastern europe middle east africa region sales japan also increased due increased usage triple combination therapy xeloda colorectal stomach breast cancer xeloda regional sales change sales sales mchf mchf cer united states europe japan international total sales sales declined across regions following entry generic competitors key markets anemia franchise neorecormonepogin mircera anemiarenal anemia declining highly competitive market combined sales roches neorecormon chugais epogin epoetin beta declined following previous periods sustained decline increased sales mircera partly compensated neorecormonepogin regional sales change sales sales mchf mchf cer united states europe japan international total sales roche finance report roche group financial review mircera regional sales change sales sales mchf mchf cer united states europe japan international total sales mircera sales growth resulted new outlicensing partnership underlying growth international region cellcept prevention solid organ transplant rejection cellcept regional sales change sales sales mchf mchf cer united states europe japan international total sales sales declined globally due continuing generic competition tamiflu influenza b tamiflu regional sales change sales sales mchf mchf cer united states europe japan international total sales sales grew mainly due epidemic influenza season us increased sales europe pandemic use addition sales increased japan due earlier onset flu season resulting higher demand fourth quarter zelboraf braf mutationpositive metastatic melanoma zelboraf regional sales change sales sales mchf mchf cer united states europe japan international total sales sales declined us due significant competition increase international region result good uptake markets brazil argentina roche finance report financial review roche group pharmaceuticals division sales region change sales sales region mchf mchf cer united states europe japan international eemea latin america asiapacific regions total sales eastern europe middle east africa united states sales grew led franchise well tamiflu xolair avastin actemraroactemra base results also benefited release sales reserves b program excluding impact million swiss francs us sales rose leading products oncology medicines mabtherarituxan avastin herceptin sales billion swiss francs billion swiss francs billion swiss francs respectively addition xolair actemra roactemra significant growth drivers tamiflu sales increased xolair sales benefited approval treat form chronic hives growth negatively impacted decline xeloda offpatent us europe sales increased led breast cancer franchise higher demand mabtherarituxan avastin mabtherarituxan sales grew due increased market share follicular lymphoma chronic lymphocytic leukemia lower mandatory rebates avastin grew due demand ovarian breast cancer addition continued sales growth actemraroactemra higher tamiflu sales due pandemic stocking growth partially offset lower sales xeloda due loss exclusivity pegasys japan sales grew major growth driver franchise increased demand avastin breast cancer well ovarian cancer malignant glioma also actemraroactemra significant uptake new subcutaneous form also strong growth edirol bonviva sales international sales increased driven volume growth latin america subregion particular brazil argentina growth latin america mainly due franchise oncology products especially avastin mabtherarituxan asiapacific main drivers growth also franchise together mabthera rituxan actemraroactemra sales china grew higher franchise mabtherarituxan offset decline sales tarceva base effect strong tamiflu sales eastern europe middle east africa subregion lower sales russia result economic conditions fourth quarter middle east following distribution changes pharmaceuticals division sales e leading emerging markets change sales sales country mchf mchf cer brazil china india mexico russia south korea turkey total sales total sales e key emerging markets stable growth china brazil offsetting impacts economic conditions fourth quarter russia public sector inventory management mexico roche finance report roche group financial review operating results pharmaceuticals division royalties operating income change mchf mchf cer royalty income income outlicensing agreements income disposal products total ifrs core basis increase royalties operating income constant exchange rates due higher income product disposals majority income arose divestment gain million swiss francs sale filgrastim franchise rights back amgen royalty income increased due higher sales eylea lucentis humira pharmaceuticals division cost sales change mchf mchf cer manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements impairment property plant equipment cost sales core basis business combinations inventory fair value adjustment global restructuring plans amortisation intangible assets total ifrs basis core cost sales increased constant exchange rates line growth sales manufacturing cost goods sold period costs increased less sales royalty expenses slightly higher impact higher tamiflu sales offset base impact additional back royalty expenses sanofi arbitration expenses collaboration profitsharing agreements increased mainly due growing sales xolair noncore costs include writeoff inventory fair value adjustment intermune acquisition accounting far relates sales remaining million swiss francs adjustment expensed acquired inventory sold comparative global restructuring costs site consolidation activities include income million swiss francs reversal previously incurred impairment charges vacaville site california amortisation intangible assets increased due esbriet intangible assets acquired part intermune acquisition pharmaceuticals division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis marketing distribution core costs increased constant exchange rates percentage sales increased marketing efforts supported newly launched products perjeta kadcyla well established oncology products key markets intermune acquisition led increase costs launch esbriet investments also made enable continued growth emerging markets increased patient access medicines bad debt expenses million swiss francs recorded income million swiss francs result increased credit risk certain customers international sales region release income allowances southern europe comparative period roche finance report financial review roche group pharmaceuticals division research development change mchf mchf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core research development costs increased constant exchange rates percentage sales rose continued investments oncology franchise notably pdltargeted therapy also alectinib recently approved japan neuroscience therapeutic area remained key area programmes multiple sclerosis alzheimers disease immunology therapeutic area lower spending cardiovascular metabolism following previously announced reorganisation pharmaceuticals divisions research development activities termination aleglitazar addition pharmaceuticals division invested million swiss francs inlicensing pipeline compounds technologies capitalised intangible assets global restructuring costs million swiss francs recorded consisting mainly employeerelated costs resulting implementation outsourced model clinical trial monitoring activities impairment charges million swiss francs resulting mainly decisions stop development various compounds pharmaceuticals division general administration change mchf mchf cer administration pensions past service costs gains losses disposal property plant equipment gains losses divestment subsidiaries business taxes capital taxes general items general administration core basis global restructuring plans impairment goodwill alliances business combinations legal environmental settlements pensions settlement gains losses total ifrs basis general administration core costs increased constant exchange rates percentage sales increased reflects base effect income recorded past service costs changes groups pension plans switzerland uk million swiss francs increase administration costs mainly result costs implementing global efficiency initiative enhancing procurement processes related systems significant increase business taxes including costs us branded prescription drug fee million swiss francs million swiss francs july us internal revenue service irs issued final regulations related fee fundamentally changed key assumption triggering event liability recognition result onetime double charge operating profit impact million swiss francs noncore costs include impairment goodwill marcadia acquisition following exit cardiovascular metabolic diseases impairments dedicated goodwill related certain previous acquisitions alliance business combination costs include mainly transaction fees related costs intermune acquisitions legal environmental settlements costs million swiss francs recorded respect fine paid italian antitrust authority regarding allegations avastin lucentis italy roche strongly disagrees allegations appealed see note consolidated financial statements details matter roche finance report roche group financial review roche pharmaceuticals chugai subdivisional operating results pharmaceuticals subdivisional operating results millions chf roche pharmaceuticals pharmaceuticals chugai division sales external customers within division core operating profit margin sales external customers operating profit margin sales external customers operating free cash flow margin sales pharmaceuticals division total core operating profit operating profit include elimination million swiss francs million swiss francs unrealised inter company profits roche pharmaceuticals chugai fall exchange rate japanese yen negative impact approximately chugai results expressed swiss francs sales external customers chugai increased japanese yen main drivers franchise avastin sales actemraroactemra roche pharmaceuticals also significantly higher chugais core operating profit increased due impacts product mix japanese yen depreciation cost sales operating free cash flow chugai decreased mainly result increase accounts receivable higher investments property plant equipment manufacturing research facilities financial position pharmaceuticals division net operating assets movement movement change change transactions cta mchf mchf chf cer mchf mchf trade receivables inventories trade payables net trade working capital receivablespayables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given consolidated financial statements reconciliation balance sheet information given roche finance report financial review roche group currency translation effects balance sheet amounts compared start swiss franc weakened us dollar leading positive translation impact net operating assets december minor negative translation effects swiss franc strengthening japanese yen euro exchange rates used given pages impacts changes exchange rates december reflected numbers see also note consolidated financial statements net working capital increase constant exchange rates due increase inventories offset increase payables reduction trade receivables trade receivables decreased despite higher sales due strong collections forfaiting receivables italy shorter payment terms february payment received spain part montoro plan addition inventory fair value adjustment intermune acquisition underlying inventory levels increased ensure continuity supply patients due increases demand established products especially emerging markets inventories also increased due recently launched products actemraroactemra subcutaneous formulation kadcyla trade payables increased result improving payment terms suppliers longterm net operating assets grew significantly due increase goodwill intangible assets billion swiss francs mainly relating intermune seragon acquisitions also increases provisions contingent consideration legal restructuring provisions also property plant equipment significant investments continue made site development projects manufacturing facilities particular switzerland us china free cash flow pharmaceuticals division operating free cash flow change mchf mchf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales detailed breakdown provided pharmaceuticals divisions operating free cash flow stable billion swiss francs increased cash generation underlying business compensated increased investments property plant equipment increases net working capital noted comments financial position operating profit net operating cash adjustments increased core operating profit increased difference mainly due significant noncash items including income changes groups pension plans increasing capital expenditure property plant equipment reflects significant investments made site development manufacturing expansion projects particularly switzerland us china roche finance report roche group financial review diagnostics division operating results diagnostics division operating results change change mchf mchf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results core eps sales diagnostics division continued increase sales growth constant exchange rates billion swiss francs professional diagnostics sales growth main growth contributor led immunodiagnostics business molecular diagnostics sales increased growth underlying molecular businesses partly offset decline genome sequencing business diabetes care sales despite continued challenging market environment notably us growth tissue diagnostics driven advanced staining franchise diagnostics division sales business area change sales sales business area mchf mchf cer professional diagnostics diabetes care molecular diagnostics tissue diagnostics total sales roche finance report financial review roche group professional diagnostics increase sales business area major contributor divisional performance regions growth primarily driven immunodiagnostics business represents divisional sales growth supported clinical chemistry business coagulation monitoring elecsys syphilis immunoassay antimllerian hormone test launched new instrument cobas launched fully automated urinalysis combining urine strip testing digital microscopy professional diagnostics regional sales change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales professional diagnostics business growing regions especially asiapacific emea due strong sales china germany north america region strong growth reported clinical chemistry immunodiagnostic businesses diabetes care sales despite continuing challenging market conditions blood glucose monitoring portfolio major markets like us sales premium product accuchek mobile grew accuchek avivaperforma sales accuchek insight system insulin delivery system combining insulin pump blood glucose meter accuchek connect webbased blood glucose meter support diabetes care selfmanagement launched europe diabetes care regional sales change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales sales north america due medicare reimbursement cut strips lower pump sales us changes number reimbursed strips canada offset increased sales emea region asiapacific latin america regions mainly driven china argentina progress made implementation specific initiatives roche diabetes care initiated goal streamline processes decisionmaking drive efficiencies continuing develop innovative solutions molecular diagnostics sales grew underlying molecular business major contributions coming virology portfolio hpv assay partly offset sales decline genome sequencing business molecular diagnostics regional sales change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales regionally growth driven north america cobas systems two integrated fully automated molecular testing systems launched blood screening virology assays also authorities australia canada us approved cobas hpv test firstline primary screening cervical cancer three diagnostics tests mrsasa cdifficile hsv launched cemarked countries expand menu cobas roche molecular diagnostics acquired genia technologies developing singlemolecule semiconductorbased dnasequencing platform using nanopore technology bina technologies developing commercialising binagms support multiple sequencing technologies iquum focused developing pointofcare products molecular diagnostics market roche finance report roche group financial review following reorganisation former applied science business area realtime pcr technology nap nucleic acid purification portfolio biochemical reagents part molecular diagnostics business sales sequencing business reported part results molecular diagnostics tissue diagnostics sales rose driven growth advanced staining portfolio cintec franchise cervical cancer diagnosis grew showing continued good uptake tissue diagnostics regional sales change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales regionally growth driven emea north america despite reimbursement changes us regions growth driven advanced staining portfolio sales asiapacific grew china main market revenues existing external partnerships showed continued growth impairments million swiss francs goodwill million swiss francs product intangible assets recorded tissue diagnostics factors leading impairments return latestage product development project predesign phase led decrease forecasted cash flows combined reduced revenue expectations us following additional reimbursement cuts change discount rate resulted impairments diagnostics division sales region change sales sales region mchf mchf cer europe middle east africa emea north america asiapacific latin america japan total sales sales growth diagnostics division driven asiapacific emea north america regions mainly professional diagnostics sales increase asiapacific driven strong performance china due governmental healthcare investments public demand divisions expanding presence wide portfolio emea region divisions largest market sales increased led growth professional diagnostics latin america region sales increased driven mainly growth professional diagnostics diabetes care sales japan remained stable roche finance report financial review roche group diagnostics division sales e leading emerging markets change sales sales country mchf mchf cer brazil china india mexico russia south korea turkey total sales e markets contributed sales growth mainly professional diagnostics business area due growth china explained operating results diagnostics division royalties operating income change mchf mchf cer royalty income income outlicensing agreements income disposal products total ifrs core basis increase constant exchange rates driven higher outlicensing income mainly molecular diagnostics diagnostics division cost sales change mchf mchf cer manufacturing cost goods sold period costs royalty expenses impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core cost sales increased constant exchange rates primarily due increase manufacturing cost goods sold period costs result volume growth additionally period costs included onetime vat refund million swiss francs related meter placements cost sales ratio compared global restructuring costs incurred mainly due reorganisation diabetes care business course autonomy speed project reorganisation former applied science business closure site graz austria amortisation product intangibles decreased intangible assets became fully amortised addition product intangible asset impairment charges million swiss francs incurred tissue diagnostics diabetes care roche finance report roche group financial review diagnostics division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis marketing distribution core costs constant exchange rates reflecting higher spending professional diagnostics driven marketing support sales force expenses partially offset lower bad debt expenses north america marketing distribution costs decreased significantly due lower field force expenses decrease offset higher expenses asiapacific latin america regions penetrate emerging markets core basis marketing distribution costs percentage sales compared global restructuring costs mainly due initiatives improve efficiency marketing distribution activities within reorganisations diabetes care former applied science businesses diagnostics division research development change mchf mchf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core research development costs increased constant exchange rates driven increased spending next generation sequencing following acquisition genia professional diagnostics core platform investments immunodiagnostics workflow automation coagulation hematology pointofcare percentage sales research development core costs decreased global restructuring costs mainly due closure site graz austria reorganisation applied science business impairment charges million swiss francs tissue diagnostics business following return latestage product development project predesign phase diagnostics division general administration change mchf mchf cer administration pensions past service costs gains losses disposal property plant equipment business taxes capital taxes general items general administration core basis global restructuring plans impairment goodwill intangible assets alliances business combinations legal environmental settlements pensions settlement gains losses total ifrs basis general administration core costs increased constant exchange rates due base effect onetime income million swiss francs recorded past service costs changes groups pension plans switzerland excluding base effect core costs increased business taxes included costs million swiss francs medical device excise tax us percentage sales core costs increased global restructuring costs mainly due projects reorganisation diabetes care addition goodwill impairment charges million swiss francs incurred tissue diagnostics business area roche finance report financial review roche group financial position diagnostics division net operating assets movement movement change change transactions cta mchf mchf chf cer mchf mchf trade receivables inventories trade payables net trade working capital receivablespayables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow include cash movements full consolidated balance sheet given consolidated financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts compared start swiss franc weakened us dollar leading positive translation impact net operating assets december partly offset negative translation effect swiss franc strengthening euro diagnostics division significant net asset position japanese yen appreciation swiss franc japanese yen minor impact exchange rates used given pages impacts changes exchange rates december reflected numbers see also note consolidated financial statements net working capital net trade working capital increased driven increase inventories accounts receivables partially offset increase trade payables inventories increased due higher demand emerging markets notably china turkey brazil trade payables increased result improving payment terms suppliers trade receivables increased due stronger sales partially offset improved collections factoring initiatives southern europe february payment received spain part montoro plan net liability receivablespayables increased due increase payables offsetting vat receivables longterm net operating assets decrease constant exchange rates due increase goodwill intangible assets genia iquum bina acquisitions offset impairments tissue diagnostics business property plant equipment increased slightly due site expansion projects us germany provisions increased due creation provisions million swiss francs contingent consideration arrangements genia iquum bina acquisitions roche finance report roche group financial review free cash flow diagnostics division operating free cash flow change mchf mchf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales detailed breakdown provided operating free cash flow diagnostics division billion swiss francs cash generation business offset increases net working capital noted comments financial position higher investments property plant equipment operating profit net cash adjustments increased core operating profit increased capital expenditure property plant equipment came mainly site expansions us germany roche finance report financial review roche group corporate operating results corporate operating results summary change mchf mchf cer administration pensions past service costs business taxes capital taxes general items general administration costs core basis global restructuring plans alliances business combinations legal environmental settlements pensions settlement gains losses total costs ifrs basis financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow see pages definition core results core eps general administration core costs increased constant exchange rates due base effect income million swiss francs recorded past service costs changes groups pension plans switzerland uk excluding costs decreased due reduced project expenses administration expenses increased due higher spending legal corporate activities total costs ifrs basis decreased legal environmental settlement expenses corporate operating free cash flow showed lower outflow compared driven lower spending foreign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth reported cer swiss francs change cer change chf pharmaceuticals division sales core operating profit diagnostics division sales core operating profit group sales core operating profit roche finance report roche group financial review exchange rates swiss franc december average december average usd eur jpy comparing average exchange rates average exchange rates swiss franc stronger currencies particular us dollar number latin american currencies japanese yen impact strongly negative income statement free cash flow results expressed swiss francs compared constant exchange rates sales developments resulted negative impact percentage points equivalent billion swiss francs translated swiss francs currency translation exposure operating profit mitigated group majority cost base located outside switzerland sensitivity group sales core operating profit absolute terms movement average foreign currency exchange rates swiss franc shown table january swiss national bank snb announced discontinuing minimum exchange rate swiss francs per euro consequence stock markets switzerland fell significantly value swiss franc increased dramatically roche group fundamental impact foreseen example group incurs less overall costs switzerland token key markets us europe japan complete value chains meaning costs incurred local currencies swiss francs impacts changes exchange rates december reflected numbers see also note consolidated financial statements since group uses swiss franc presentation currency consolidated financial statements weakening foreign currencies swiss franc negative currency translation impact groups consolidated results reported swiss francs currency translation sensitivity groups results movements foreign currency exchange rates shown currency sensitivities impact change average exchange rate sales core operating profit versus swiss franc mchf mchf us dollar euro japanese yen currencies groups revenues primarily generated sales products customers revenues mainly received local currency customers home market although certain emerging markets invoicing made major international currencies us dollar euro costs sales marketing also administration costs follow currency pattern sales majority research development activities incurred groups global research facilities therefore costs mainly concentrated us dollars swiss francs euros general administration costs tend incurred mainly central locations us switzerland germany obviously large majority chugais costs denominated japanese yen roche finance report financial review roche group treasury taxation results treasury taxation results change change mchf mchf chf cer ifrs results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests financial position treasury taxation net debt pensions income taxes financial noncurrent assets derivatives net collateral net interest payable nonoperating assets net total net assets liabilities free cash flow treasury taxation treasury activities taxes paid dividends paid total see pages definition core results core eps financing costs financing costs ifrs basis higher constant exchange rates mainly due loss major debt restructuring million swiss francs core financing costs lower driven decrease interest expenses reflects continued repayment debt incurred finance genentech transaction new debt issued late finance intermune acquisition major impact financing costs net interest cost defined benefit pension plans decreased million swiss francs due improved funding status end full analysis financing costs given note consolidated financial statements roche finance report roche group financial review financial income expense financial income expense net income million swiss francs compared expense million swiss francs reason income equity securities million swiss francs million swiss francs major factor sale equity security position late resulting income million swiss francs interest income income debt securities million swiss francs environment continuing low interest rates net foreign exchange result reflects hedging costs loss million swiss francs compared loss million swiss francs full analysis financial income expense given note consolidated financial statements details groups hedging arrangement given note income taxes groups effective core tax rate increased percentage points mainly due higher percentage core profit contribution coming tax jurisdictions relatively higher local tax rates average group tax rate notably us addition effective tax rate includes retrospective reenactment us research development tax credits means results included two years tax credits respect well ifrs results include noncore expenses coming tax jurisdictions relatively higher tax rates groups effective tax rate therefore decreasing effective tax rate ifrs results compared core results impact partially offset fact ifrs results also include goodwill impairments tax deductible full details groups income tax positions given note consolidated financial statements analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate mchf mchf mchf mchf groups effective tax rate core basis global restructuring plans goodwill intangible assets alliances business combinations legal environmental major debt restructuring equity compensation plans groups effective tax rate ifrs basis financial position increase net debt mainly due outflows business combinations billion swiss francs partially offset free cash flow billion swiss francs increase net pension liabilities reflects lower interest rates leading discounted defined benefit obligation higher net tax position decreased mainly due deferred tax effects acquisition accounting increased net pension liabilities december group held financial longterm assets market value billion swiss francs consist mostly holdings biotechnology companies acquired context licensing transactions scientific collaborations weakening swiss franc us dollar year led translation impact groups us dollardenominated debt increased net debt swiss franc terms impacts changes exchange rates december reflected numbers see also note consolidated financial statements free cash flow sales equity securities lower interest payments led decrease cash outflow treasury activities billion swiss francs taxes paid billion swiss francs decrease constant exchange rates mainly due prepayments tax dividends payments billion swiss francs increase billion swiss francs compared reflecting increase roche group dividend roche finance report financial review roche group cash flows net debt operating free cash flow billions chf free cash flow billions chf free cash flow millions chf pharmaceuticals diagnostics corporate group operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid dividends paid free cash flow operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid dividends paid free cash flow operating free cash flow billion swiss francs strong underlying cash generation business part used capital expenditure projects restructuring initiatives resulting decrease constant exchange rates net working capital increased notably inventories cash outflow treasury activities lower billion swiss francs mostly due sales equity securities reduced interest payments total taxes paid billion swiss francs decrease due prepayments tax total dividends paid higher due increase annual roche group dividend free cash flow billion swiss francs higher constant exchange rates sales equity securities lower interest tax payments offset increase dividend roche finance report roche group financial review net debt millions chf december cash cash equivalents marketable securities longterm debt shortterm debt net debt beginning period change net debt free cash flow transactions equity instruments business combinations net divestments subsidiaries hedging collateral arrangements currency translation fair value movements change net debt period december cash cash equivalents marketable securities longterm debt shortterm debt net debt end period net debt currency profile millions chf cash marketable securities debt us dollar euro swiss franc japanese yen pound sterling total us dollardenominated debt includes bonds notes denominated euros swiss francs pounds sterling swapped us dollars therefore financial statements economic characteristics equivalent us dollardenominated bonds notes net debt position group december billion swiss francs increase billion swiss francs december increase net debt mainly due billion swiss francs outflow business combinations partially offset free cash flow billion swiss francs includes annual dividend payment billion swiss francs transactions equity hedge groups employee stock option programmes totalled billion swiss francs group entered derivative contracts third parties hedge foreign exchange risk arising bonds notes issued currencies us dollar time collateral agreements entered derivative counterparties mitigate counterparty risk cash collateral balance decreased billion swiss francs collateral balance relation hedges nonus dollardenominated bonds notes mainly sensitive foreign exchange rate us dollar euro also pound sterling currently collateral balance moves approximately million us dollars foreign exchange rates move simultaneously redemption repurchase bonds notes see note consolidated financial statements impact liquid funds impact net debt position roche finance report financial review roche group pensions postemployment benefits postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans million swiss francs million swiss francs plans classified defined benefit plans even groups potential obligation minor relatively remote possibility arising plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources defined benefit plans expenses groups defined benefit plans million swiss francs million swiss francs increase mainly due base effect past service income million swiss francs partly offset decrease current service cost million swiss francs driven higher discount rates beginning compared beginning based revised actuarial assumptions end expenses groups defined benefit plans expected approximately million swiss francs driven lower discount rates beginning estimates pension expenses include settlement past servicecurtailment effects might arise year operating income million swiss francs recorded past service costs changes groups pension plans switzerland uk germany represents onetime impact adjustment pension liability plan changes amount million swiss francs recorded pharmaceuticals division million swiss francs diagnostics division remaining million swiss francs income allocated corporate mainly attributable previously divested businesses funding status balance sheet position mchf mchf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability overall funding status ifrs basis groups defined benefit plans decreased compared start year change came mainly increase defined benefit obligation arising fall discount rates germany switzerland us since end use updated mortality tables us increased defined benefit obligation million swiss francs plan assets increased mainly due increases market values investments funded status pension funds monitored local pension fund governance bodies well closely reviewed group level full details groups pensions postemployment benefits given note consolidated financial statements roche finance report roche group financial review roche shares share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billions chf roche ranked number among peer group consisting roche healthcare companies total shareholder return tsr defined share price growth plus dividends measured swiss francs actual exchange rates constant exchange rates roche ranked number yearend return roche shares roche nonvoting equity securities combined performance share nonvoting equity security compared weighted average return peer group swiss franc terms constant exchange rates healthcare sector outperformed major segments general market despite continued pricing pressure government budget constraints many parts world roche shares performed strongly throughout year announcement marianne trial results late december affected closing value peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer roche sanofi takeda total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source datastream data roche peer index rebased january peer index converted chf daily actual exchange rates currency fluctuations influence representation relative performance roche versus peer index roche finance report financial review roche group proposed dividend board directors proposing increase dividend swiss francs per share nonvoting equity security swiss francs approval annual general meeting th consecutive increase dividend dividend proposal approved shareholders dividend payments total shares nonvoting equity securities amount billion swiss francs billion swiss francs resulting payout ratio based core net income based prices yearend dividend yield roche share yield nonvoting equity security information roche securities given pages information per share nonvoting equity security change chf chf chf eps basic eps diluted core eps basic core eps diluted equity attributable roche shareholders per share dividend per share details please refer notes consolidated financial statements payout ratio calculated dividend per share divided core earnings per share debt finance genentech transaction group issued bonds notes equivalent billion swiss francs debt raised early repaid december billion us dollardenominated notes redeemed following exercise earlycall option december billion pounds sterling billion us dollars notes repurchasedredeemed later year december group resolved exercise option call early redemption billion us dollars notes due march notes repaid march group financed intermune acquisition primarily raising net proceeds billion us dollars debt offering described note consolidated financial statements remaining financing achieved groups funds issuing commercial paper result low interest rates capital markets group decided november restructure part debt includes early partial redemptions billion us dollardenominated notes originally due march july refinanced issuing billion us dollardenominated notes due september november major debt restructuring resulted loss repurchase million swiss francs transactions described note consolidated financial statements maturity schedule groups bonds notes outstanding december shown table includes instruments already issue prior genentech transaction roche finance report roche group financial review bonds notes nominal amounts december contractual maturity us dollar euro pound sterling swiss franc total total musd meur mgbp mchf musd mchf beyond total total translated december exchange rates proceeds bonds notes billion euros swapped us dollars therefore financial statements bonds notes economic characteristics equivalent us dollardenominated bonds notes proceeds bonds notes million pounds sterling swapped us dollars therefore financial statements bonds notes economic characteristics equivalent us dollardenominated bonds notes group plans meet debt obligations using existing liquid funds well cash generated business operations free cash flow billion swiss francs included cash generated operations well payment interest tax dividends shortterm financing requirements group commercial paper programme us issue billion us dollars unsecured commercial paper notes committed credit lines billion euros available backstop lines commercial paper notes totalling billion us dollars outstanding december december billion us dollars longerterm financing group maintains strong longterm investmentgrade credit ratings aa standard poors moodys facilitate efficient access international capital markets credit ratings roche group december shortterm longterm outlook moodys p stable standard poors aa stable financial risks december group net debt position billion swiss francs billion swiss francs financial assets group managed conservative way objective meet groups financial obligations times asset allocation considerable portion cash marketable securities group currently holds used debt redemptions liquid funds either held cash invested highquality investmentgrade fixed income securities investment horizon meet liquidity requirements cash marketable securities mchf total mchf total cash cash equivalents money market instruments debt securities equity securities total cash marketable securities roche finance report financial review roche group credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group rating profile groups billion swiss francs cash fixed income marketable securities remained strong invested aaaa range noted previously group signed netting collateral agreements counterparties order mitigate counterparty risk derivative positions group trade receivables billion swiss francs since beginning increasing financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries december trade receivables billion euros billion swiss francs public customers countries decrease billion euros december mainly due forfaiting italy collections spain part montoro plan group uses different measures improve collections countries including intense communication customers forfaiting negotiations payment plans charging interest late payments legal actions group applying new commercial policies selected hospitals greece portugal italy since groups trade receivables balance southern europe decreased liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time addition current liquidity position group strong cash generation ability future cash flows used repay debt instruments coming years roche enjoys strong longterm investmentgrade credit ratings aa standard poors moodys time roche rated highest available shortterm ratings agencies event financing requirements ratings strong credit roche permit efficient access international capital markets including commercial paper market group committed credit lines various financial institutions totalling billion swiss francs billion swiss francs serve back stop line commercial paper programme december debt drawn credit lines market risk market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes interest rates foreign exchange rates equity prices group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices groups var remained largely stable interest rate risk interest rate risk arises movements interest rates could affect group financial result value group equity group may use interest rate derivatives manage interestraterelated exposure financial result information financial risk management financial risks var methodology included note consolidated financial statements international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since group implemented various minor amendments existing standards interpretations material impact groups overall results financial position group currently assessing potential impacts various new revised standards interpretations mandatory january group yet applied based analysis date group anticipate material impact groups overall results financial position group also assessing new revised standards mandatory notably ifrs financial instruments ifrs revenues contracts customers roche finance report roche group roche group consolidated financial statements roche group consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche group consolidated financial statements roche group roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidated financial statements roche group consolidated statement comprehensive income millions chf year ended december net income recognised income statement comprehensive income remeasurements defined benefit plans items never reclassified income statement availableforsale investments cash flow hedges currency translation foreign operations items may reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholders noncontrolling interests total roche finance report roche group consolidated financial statements roche group roche group consolidated balance sheet millions chf december december december noncurrent assets property plant equipment goodwill intangible assets deferred tax assets defined benefit plan assets noncurrent assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred tax liabilities defined benefit plan liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity roche finance report roche group roche group consolidated financial statements roche group consolidated statement cash flows millions chf year ended december cash flows operating activities cash generated operations increase decrease net working capital payments made defined benefit plans utilisation provisions disposal products operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets business combinations divestment subsidiaries interest dividends received sales marketable securities purchases marketable securities investing cash flows total cash flows investing activities cash flows financing activities proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt hedging collateral arrangements equity contribution noncontrolling interests interest paid dividends paid equitysettled equity compensation plans net transactions equity financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december roche finance report roche group consolidated financial statements roche group roche group consolidated statement changes equity millions chf non share retained fair value hedging translation controlling total capital earnings reserves reserves reserves total interests equity year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests equity contribution noncontrolling interests december year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests equity contribution noncontrolling interests december roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles basis preparation consolidated financial statements hereafter annual financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except items required accounted fair value approved issue board directors january subject approval annual general meeting shareholders march financial statements annual financial statements roche holding ltd company registered switzerland subsidiaries group groups significant accounting policies changes accounting policies disclosed note key accounting judgements estimates assumptions preparation annual financial statements requires management make judgements estimates assumptions affect reported amounts revenues expenses assets liabilities contingent amounts actual outcomes could differ management estimates estimates underlying assumptions reviewed ongoing basis based historical experience various factors revisions estimates recognised period estimate revised following considered key accounting judgements estimates assumptions made believed appropriate based upon currently available information revenue nature groups business many sales transactions simple structure may consist multiple components occurring different times group also party outlicensing agreements involve upfront milestone payments occurring several years may also involve certain future obligations revenue recognised managements judgement significant risks rewards ownership transferred group retain continuing managerial involvement effective control goods sold obligation fulfilled transactions result cash receipts initially recognised deferred income released income subsequent periods basis performance conditions specified agreement may circumstances level sales returns hence revenues reliably measured cases sales recognised right return expires generally upon prescription products patients order estimate management uses publicly available information prescriptions well information provided wholesalers intermediaries december group million swiss francs provisions accruals expected sales returns chargebacks rebates including medicaid us similar rebates countries estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience december group million swiss francs provisions doubtful receivables see note estimates based analyses ageing customer balances specific credit circumstances historical trends groups experience taking also account current economic conditions business combinations group initially recognises fair value identifiable assets acquired liabilities assumed non controlling interest consideration transferred business combination management judgement particularly involved recognition fair value measurement intellectual property inventories contingent liabilities contingent consideration making assessment management considers underlying economic substance items concerned addition contractual terms roche finance report notes roche group consolidated financial statements roche group impairment december group million swiss francs property plant equipment see note million swiss francs goodwill see note million swiss francs intangible assets see note goodwill intangible assets yet available use reviewed annually impairment property plant equipment intangible assets use assessed impairment triggering event provides evidence asset may impaired assess whether impairment exists estimates expected future cash flows used actual outcomes could vary significantly estimates factors changes discount rates planned use buildings machinery equipment closure facilities presence competition technical obsolescence lower anticipated product sales could lead shorter useful lives impairment pensions postemployment benefits group operates number defined benefit plans fair values recognised plan assets liabilities based upon statistical actuarial calculations measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions december present value groups defined benefit obligation million swiss francs see note actuarial assumptions used may differ materially actual results due changes market economic conditions longer shorter life spans participants changes factors assessed differences could impact defined benefit plan assets liabilities recognised balance sheet future periods legal provisions group provides anticipated legal settlement costs probable outflow resources reliably estimated december group million swiss francs legal provisions status significant legal cases disclosed note estimates consider specific circumstances legal case relevant legal advice inherently judgemental due highly complex nature legal cases estimates could change substantially time new facts emerge legal case progresses reliable estimate made provision recorded contingent liabilities disclosed material environmental provisions group provides anticipated environmental remediation costs probable outflow resources reasonably estimated december group million swiss francs environmental provisions see note environmental provisions consist primarily costs fully clean refurbish contaminated sites including landfills treat contain contamination certain sites estimates inherently judgemental due uncertainties related detection previously unknown contamination method extent remediation percentage problematic materials attributable group remediation sites financial capabilities potentially responsible parties estimates could change substantially time new facts emerge environmental remediation progresses contingent consideration provisions group makes provision estimated fair value contingent consideration arrangements arising business combinations december group million swiss francs contingent consideration provisions see note total payments contingent consideration arrangements could million swiss francs see note estimated amounts provided expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario discounted net present value estimates could change substantially time new facts emerge scenario develops income taxes december group current income tax net liability million swiss francs deferred tax net asset million swiss francs see note significant estimates required determine current deferred tax assets liabilities estimates based interpretations existing tax laws regulations factors may impact current deferred taxes include changes tax laws regulations rates changing interpretations existing tax laws regulations future levels research development spending changes pretax earnings leases treatment leasing transactions mainly determined whether lease considered operating finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered assessments consolidation group periodically undertakes transactions may involve obtaining control significant influence companies transactions include equity acquisitions asset purchases alliance agreements transactions structured entities cases management makes assessment whether group control significant influence company whether consolidated subsidiary accounted associated company making assessment management considers underlying economic substance transaction addition contractual terms roche finance report roche group notes roche group consolidated financial statements operating segment information group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenues sale licensing products technology third parties residual operating activities divested businesses certain global activities reported corporate include corporate executive committee global group functions communications human resources finance including treasury taxes pension fund management legal safety environmental services sub divisional information roche pharmaceuticals chugai operating segments within pharmaceuticals division also presented divisional information millions chf pharmaceuticals diagnostics corporate group revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure research development research development costs segment information depreciation property plant equipment amortisation intangible assets impairment reversal property plant equipment impairment goodwill impairment intangible assets equity compensation plan expenses roche finance report notes roche group consolidated financial statements roche group pharmaceuticals subdivisional information millions chf roche pharmaceuticals chugai pharmaceuticals division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination income within division total segment results operating profit elimination profit within division operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure research development research development costs elimination costs within division total segment information depreciation property plant equipment amortisation intangible assets impairment reversal property plant equipment impairment goodwill impairment intangible assets equity compensation plan expenses net operating assets millions chf assets liabilities net assets pharmaceuticals diagnostics corporate total operating nonoperating group net operating assets pharmaceuticals subdivisional information millions chf assets liabilities net assets roche pharmaceuticals chugai elimination within division pharmaceuticals division roche finance report roche group notes roche group consolidated financial statements information geographical area millions chf revenues external customers noncurrent assets royalties property plant goodwill sales operating income equipment intangible assets switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total supplementary unaudited information sales therapeutic areas pharmaceuticals division business areas diagnostics division given financial review sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenue major customers total three us national wholesale distributors represent approximately quarter groups revenues three us national wholesale distributors amerisourcebergen corp billion swiss francs billion swiss francs mckesson corp billion swiss francs billion swiss francs cardinal health inc billion swiss francs billion swiss francs approximately revenues pharmaceuticals operating segment residual diagnostics segment roche finance report notes roche group consolidated financial statements roche group net financial expense financing costs millions chf interest expense amortisation debt discount net gains losses redemption repurchase bonds notes loss major debt restructuring discount unwind net interest cost defined benefit plans total financing costs financial income expense millions chf net gains losses sale equity securities net gains losses equity security derivatives dividend income writedowns impairments equity securities net income equity securities interest income net gains losses sale debt securities net interest income income debt securities net foreign exchange gains losses net gains losses foreign currency derivatives foreign exchange gains losses net financial income expense associates total financial income expense net financial expense millions chf financing costs financial income expense net financial expense financial result treasury management financial result pension management associates net financial expense roche finance report roche group notes roche group consolidated financial statements income taxes income tax expenses millions chf current income taxes deferred taxes total income tax expense since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year year due changes mix groups taxable income changes local tax rates groups average expected tax rate decreased main driver decrease due lower proportion groups profits us relatively higher local tax rate average group rate lower proportion us profits driven goodwill impairments significant local tax rate changes main operating areas group compared groups effective tax rate increased mainly due goodwill impairments mentioned tax deductible utilisation previously unrecognised tax losses addition effective tax rate includes retrospective reenactment us research development tax credits means results included two years tax credits respect well groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect nontaxable incomenondeductible expenses equity compensation plans research development manufacturing tax credits us state tax impacts tax unremitted earnings utilisation previously unrecognised tax losses differences groups effective tax rate income tax benefit recorded respect equity compensation plans varies according price underlying equity million swiss francs million swiss francs income tax benefits recorded solely basis ifrs expense multiplied applicable tax rate benefit approximately million swiss francs million swiss francs would recorded tax effects comprehensive income millions chf pretax aftertax pretax aftertax amount tax amount amount tax amount remeasurements defined benefit plans availableforsale investments cash flow hedges currency translation foreign operations comprehensive income roche finance report notes roche group consolidated financial statements roche group income tax assets liabilities millions chf current income taxes assets liabilities net current income tax assets liabilities deferred taxes assets liabilities net deferred tax assets liabilities current income taxes movements recognised net assets liabilities millions chf net current income tax asset liability january income taxes paid business combinations charged credited income statement charged credited equity equity compensation plans transactions shareholders currency translation effects net current income tax asset liability december deferred taxes movements recognised net assets liabilities millions chf property plant intangible defined temporary equipment assets benefit plans differences total year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects december year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects december deferred tax net assets temporary differences mainly relates accrued liabilities provisions unrealised profit inventory roche finance report roche group notes roche group consolidated financial statements deferred tax assets recognised tax losses carried forward extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows unrecognised tax losses expiry amount applicable tax amount applicable tax mchf rate mchf rate within one year one five years five years total unrecognised tax losses five years category includes losses used us state income tax purposes states permit tax reporting separate entity basis deferred tax liabilities established withholding tax taxes would payable remittance earnings foreign subsidiaries amounts currently regarded permanently reinvested total unremitted earnings group regarded permanently reinvested billion swiss francs december billion swiss francs business combinations acquisitions acquisitions net assets acquired millions chf pharmaceuticals diagnostics total intangible assets product intangibles use product intangibles available use technology intangibles use deferred tax assets inventories accounts receivable marketable securities cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration cash deferred consideration contingent consideration settlement preexisting relationship total consideration pharmaceuticals seragon pharmaceuticals inc august group acquired controlling interest seragon pharmaceuticals inc seragon us private company based san diego california acquisition group obtained rights seragons entire portfolio selective estrogen receptor degraders serds potential treatment hormone receptorpositive cancers seragons lead product candidate arn nextgeneration serd currently phase clinical trials patients roche finance report notes roche group consolidated financial statements roche group hormone receptorpositive breast cancer failed current hormonal agents seragon reported pharmaceuticals division total consideration million us dollars million us dollars paid cash million us dollars deferred cash consideration paid period date control end february million us dollars arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero billion us dollars santaris pharma september group acquired controlling interest santaris pharma santaris private company based near copenhagen denmark santaris pioneered proprietary locked nucleic acid lna platform contributed emerging era rnatargeting therapeutics new class medicines potential address difficult treat diseases range therapeutic areas santaris reported pharmaceuticals division total consideration million us dollars million us dollars paid cash million us dollars arose contingent consideration arrangement million us dollars arose settlement preexisting relationship contingent payments based achievement performancerelated milestones range undiscounted outcomes zero million us dollars intermune inc august group announced entered merger agreement intermune inc intermune fully acquire intermune price us dollars per share allcash transaction september group acquired controlling interest intermune publicly owned us company based brisbane california listed nasdaq acquisition added new medicine idiopathic lung fibrosis esbriet groups portfolio esbriet approved fda october idiopathic lung fibrosis progressive disease causes scarring lungs survival rate two three years diagnosis esbriet potential make considerable difference treatment patients debilitating disease intermune reported pharmaceuticals division total consideration billion us dollars paid cash september group issued billion us dollars aggregate principal amount senior notes part finance transaction see note dutalys gmbh december group acquired controlling interest dutalys gmbh dutalys private company based vienna austria dutalys specialises discovery development fully human bispecific antibodies based proprietary dutamab technology bispecific antibodies developed platform designed provide novel bestinclass molecules several therapeutic areas dutalys reported pharmaceuticals division total consideration million us dollars million us dollars paid cash million us dollars arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero million us dollars identifiable assets acquired liabilities assumed set table amounts seragon santaris intermune dutalys provisional based preliminary information valuations assets liabilities subject adjustment pharmaceuticals acquisitions net assets acquired millions chf seragon santaris intermune dutalys total intangible assets product intangibles use product intangibles available use technology intangibles use deferred tax assets inventories accounts receivable marketable securities cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration cash deferred consideration contingent consideration settlement preexisting relationship total consideration roche finance report roche group notes roche group consolidated financial statements fair value intangible assets determined using excess earning method based management forecasts observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate seragon santaris intermune valuations performed independent valuers intangible asset allocation dutalys based historical experience similar acquisitions valuation completed independent valuer first half fair value intermune inventories determined based estimated selling price ordinary course business less estimated costs completion sale reasonable profit margin based effort complete sell inventories intermune accounts receivable comprise gross contractual amounts due million swiss francs expected collectable date acquisition goodwill represents control premium acquired work force synergies expected integrating acquired companies groups existing business intermune control premium represents premium paid traded market price obtain control business none goodwill expected deductible income tax purposes directly attributable transaction costs million swiss francs reported pharmaceuticals operating segment within general administration expenses mainly relate intermune acquisition three months december intermune contributed revenue million swiss francs net loss million swiss francs results reported pharmaceuticals division group acquisition occurred january management estimates intermune would contributed revenue million swiss francs net loss million swiss francs information provided illustrative purposes necessarily indicative results combined group would occurred intermune actually acquired beginning year indicative future results combined group impact seragon santaris dutalys acquisitions results material diagnostics genia technologies inc june group acquired controlling interest genia technologies inc genia us private company based california genia developing singlemolecule semiconductorbased dna sequencing platform using nanopore technology genia reported diagnostics operating segment part sequencing business total consideration million us dollars million us dollars paid cash million us dollars arose contingent consideration arrangement contingent payments based achievement performancerelated milestones may arise june range undiscounted outcomes zero million us dollars iquum inc june group acquired controlling interest iquum inc iquum us private company based massachusetts iquum developed laboratoryinatube liat system enables healthcare workers perform rapid molecular diagnostic testing pointofcare setting closer patients minimal training iquum reported diagnostics operating segment part molecular diagnostics business total consideration million us dollars million us dollars paid cash million us dollars arose contingent consideration arrangement contingent payments based achievement performancerelated milestones may arise first half range undiscounted outcomes zero million us dollars addition group acquired controlling interest related intellectual property holding company cash consideration million us dollars bina technologies inc december group acquired controlling interest bina technologies inc bina us private company based redwood city california bina provides big data platform centralised management processing next generation sequencing data binas proprietary onmarket genomic management solution binagms empowers basic translational academic researchers perform fast scalable analyses maximise value genomic data acquisition bina accelerate product development global commercialisation binagms enterprise software system supporting multiple sequencing technologies developing solution roche sequencing systems bina reported diagnostics operating segment part sequencing business total consideration million us dollars million us dollars paid cash million us dollars deferred cash consideration paid period date control end million us dollars arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero million us dollars roche finance report notes roche group consolidated financial statements roche group identifiable assets acquired liabilities assumed set table amounts bina provisional based preliminary information valuations assets liabilities subject adjustment diagnostics acquisitions net assets acquired millions chf genia iquum bina total intangible assets product intangibles use product intangibles available use deferred tax assets inventories cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration cash deferred consideration contingent consideration total consideration fair value intangible assets determined using excess earning method based management forecasts observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate genia iquum valuations performed independent valuers intangible asset allocation bina based historical experience similar acquisitions valuation completed independent valuer first half goodwill represents control premium acquired work force synergies expected integrating acquired companies groups existing business none goodwill expected deductible income tax purposes directly attributable transaction costs million swiss francs reported diagnostics operating segment within general administration expenses impact genia iquum bina acquisitions results reported diagnostics division group material future acquisitions ariosa diagnostics inc december group announced agreement acquire controlling interest ariosa diagnostics inc ariosa us private company based san jose california january transaction closed ariosa molecular diagnostics testing service provider provides highly targeted accurate noninvasive prenatal testing nipt service clia laboratory using cellfree dna cfdna technology ariosas proprietary harmony prenatal test blood test performed early weeks pregnancy evaluating fetal cfdna found maternal blood test designed assess risk syndrome genetic abnormalities specifically test assesses risk trisomies indicative extra chromosome fetus lead severe genetic conditions harmony prenatal test validated clia requirements robust clinical data set supported clinical studies ariosa reported diagnostics operating segment part sequencing business purchase consideration million us dollars cash million us dollars contingent consideration arrangement roche finance report roche group notes roche group consolidated financial statements foundation medicine inc january group announced agreement enter broad strategic collaboration foundation medicine inc fmi acquire majority interest fmi fully diluted basis fmi publicly owned us company based cambridge massachusetts listed nasdaq stock code fmi group tender approximately million fmi shares us dollars per share aggregate tender value approximately million us dollars invest million us dollars acquiring million newly issued fmi shares us dollars per share closing transaction expected second quarter transaction advance fmis marketleading position molecular information genomic analysis providing group unique opportunity optimise identification development novel treatment options cancer patients partnership includes broad rd collaboration potential million us dollars funding group accelerate fmis new product development initiatives optimise treatments oncology patients better design understand results clinical trials based molecular information well commercial collaboration agreements aimed expanding global sales efforts fmis current future products planned fmi reported pharmaceuticals division trophos january group announced agreement acquire controlling interest trophos privately owned company based marseille france closing transaction expected first quarter trophos proprietary screening platform generated olesoxime tro developed spinal muscular atrophy sma rare debilitating genetic neuromuscular disease commonly diagnosed children results pivotal phase ii clinical trial olesoxime sma showed beneficial effect maintenance neuromuscular function individuals type ii nonambulatory type iii sma well reduction medical complications associated disease trophos reported pharmaceuticals division purchase consideration million euros cash million euros contingent consideration arrangement acquisitions constitution medical investors inc july group acquired controlling interest constitution medical investors inc cmi us private company based massachusetts cmi developer highly innovative hematology testing system designed provide faster accurate diagnosis bloodrelated diseases helping improve patient care cmi reported diagnostics operating segment part professional diagnostics business area total consideration million us dollars million us dollars paid cash million us dollars arose contingent consideration arrangement contingent payments based achievement performancerelated milestones may arise end range undiscounted outcomes zero million us dollars identifiable assets acquired liabilities assumed set table acquisitions net assets acquired millions chf cmi intangible assets product intangibles available use deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration cash contingent consideration total consideration cash flows business combinations acquisitions net cash outflow millions chf pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration paid deferred consideration paid contingent consideration paid cash acquired company transaction costs total net cash outflow roche finance report notes roche group consolidated financial statements roche group global restructuring plans group continued implementation several major global restructuring plans initiated prior years notably programme address longterm profitability diabetes care business diagnostics division total costs million swiss francs higher mainly due results including income million swiss francs reversal previously incurred impairment charges bulk drug production unit vacaville site california global restructuring plans costs incurred millions chf diagnostics site consolidation plans total year ended december global restructuring costs employeerelated costs site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs year ended december global restructuring costs employeerelated costs site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs split plans table reformatted prior periods reflect relative development various plans includes diabetes care autonomy speed restructuring plan includes closure nutley site associated infrastructure environmental remediation costs includes plans pharmaceuticals division research development strategic realignment intermune integration specialty care field force europe diagnostics division september roche diabetes care announced autonomy speed initiative enable business focus diabetes care specific requirements speed processes decisionmaking drive efficiencies total costs million swiss francs incurred mainly employeerelated costs consultancy costs spending smaller plans within division million swiss francs included costs related projects restructuring former applied science business roche finance report roche group notes roche group consolidated financial statements site consolidation operational closure us site nutley new jersey completed schedule end group currently process divesting site work remediating nutley site continuing significant additional restructuring expenses incurred site consolidation costs include related closure toluca mexico pharmaceuticals graz austria diagnostics sites global restructuring plans total costs million swiss francs one major item goodwill impairment million swiss francs related marcadia acquisition following exit cardiovascular metabolic diseases significant costs included million swiss francs relating field force reductions across europe pharmaceuticals divisions specialty care unit intermune integration costs million swiss francs costs million swiss francs arose implementation global outsourcing clinical trial monitoring pharmaceuticals division remaining minor plans totalled million swiss francs pharmaceuticals division announced part investments increase global biologic medicine manufacturing network capacity bulk drug production unit vacaville site california discontinued fully written put back service resulted income million swiss francs reversal previously incurred impairment charges see note global restructuring plans summary costs incurred millions chf employeerelated costs termination costs defined benefit plans employeerelated costs total employeerelated costs site closure costs impairment reversal property plant equipment accelerated depreciation property plant equipment gains losses disposal property plant equipment site closure costs total site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs roche finance report notes roche group consolidated financial statements roche group global restructuring plans classification costs millions chf depreciation depreciation amortisation amortisation impairment costs total impairment costs total cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics general administration pharmaceuticals diagnostics corporate total total operating segment roche pharmaceuticals chugai diagnostics corporate total roche finance report roche group notes roche group consolidated financial statements property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery construction land improvements equipment progress total january cost accumulated depreciation impairment net book value year ended december january additions disposals transfers depreciation charge impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january business combinations additions disposals transfers depreciation charge impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value impairment reversal charge october pharmaceuticals division announced details investments increase global biologic medicine manufacturing network capacity meet rising demand licensed biologics expected pipeline growth investments spread across sites penzberg germany basel switzerland well vacaville oceanside us bulk drug production unit vacaville site california yet licensed discontinued fully written part reassessment global manufacturing network requirements time bulk drug production unit vacaville site require capital investment become operational expected occur groups decision restart licensing efforts prepare operational use discontinued bulk drug production unit vacaville site commercial manufacturing resulted impairment reversal property plant equipment million swiss francs impairment reversal million swiss francs represents net book value time original impairment assets brought back use less depreciation would charged intervening period impairment occurred roche finance report notes roche group consolidated financial statements roche group classification impairment property plant equipment millions chf cost sales marketing distribution research development general administration total impairment reversal charge reimbursements received insurance companies respect impairments property plant equipment none borrowing costs capitalised property plant equipment none leasing arrangements group lessee finance leases december capitalised cost property plant equipment finance leases million swiss francs million swiss francs net book value assets million swiss francs million swiss francs carrying value leasing obligation million swiss francs million swiss francs reported part debt see note finance leases future minimum lease payments noncancellable leases millions chf future minimum lease present value minimum lease payments payments within one year one five years five years total future finance charges total future minimum lease payments undiscounted operating leases group companies party number operating leases mainly plant machinery including motor vehicles certain shortterm property rentals arrangements impose significant restrictions group total operating lease rental expense million swiss francs million swiss francs operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments roche finance report roche group notes roche group consolidated financial statements leasing arrangements group lessor finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method finance leases future minimum lease receipts noncancellable leases millions chf present value minimum gross investment lease lease receipts within one year one five years five years total unearned finance income na na unguaranteed residual value na na net investment lease accumulated allowance uncollectible minimum lease payments million swiss francs million swiss francs contingent rents recognised income operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements assets reported within property plant equipment lease income operating leases recognised lease term straightline basis december machinery equipment original cost million swiss francs million swiss francs net book value million swiss francs million swiss francs leased third parties contingent rents recognised income operating leases future minimum lease receipts noncancellable leases millions chf within one year one five years five years total minimum receipts capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling billion swiss francs billion swiss francs roche finance report notes roche group consolidated financial statements roche group goodwill goodwill movements carrying value assets millions chf january cost accumulated impairment net book value year ended december january business combinations impairment charge currency translation effects december cost accumulated impairment net book value allocated following cashgenerating units roche pharmaceuticals chugai total pharmaceuticals division diabetes care professional diagnostics molecular diagnostics tissue diagnostics sequencing strategic goodwill held divisional level allocated business areas total diagnostics division impairment charge impairment charges totalling million swiss francs recorded related goodwill impairment charge million swiss francs recorded full writeoff goodwill tissue diagnostics business area within diagnostics division impairment based latest business plans prepared second half factors leading impairment decrease forecasted cash flows following reassessment late stage future product development returned predesign phase combined additional us reductions immunohistochemistry testing reimbursement laboratories business plan projection period reduced ten years five years ii increase pretax discount rate used impairment testing compared addition impairments million swiss francs recorded product intangibles tissue diagnostics business see note goodwill impairment charge million swiss francs recorded pharmaceuticals division full writeoff goodwill marcadia acquisition memory acquisition arius piramed acquisitions deemed disposed roche finance report roche group notes roche group consolidated financial statements impairment charges totalling million swiss francs recorded related goodwill impairment charge million swiss francs recorded tissue diagnostics business area within diagnostics division impairment based latest business plans prepared second half main factors leading impairment reduced revenue expectations us following recent changes college american pathologists guidelines use negative reagent controls immunohistochemistry testing reduced volumes changes reduced reimbursement amount laboratories april group announced reorganisation applied science business area goodwill impairment charge million swiss francs incurred full writeoff goodwill life sciences acquisition innovatis acquisition former applied science business area impairment testing pharmaceuticals division divisions operating segments cashgenerating units used testing goodwill chugai recoverable amount based fair value less costs sell determined reference publicly quoted share prices chugai shares roche pharmaceuticals recoverable amount used impairment testing based value use cash flow projections used roche pharmaceuticals impairment testing based recent business plans approved management business plans include managements latest estimates sales volume pricing well production operating costs assume significant changes organisation business plans projected five years valuations include terminal value beyond years assuming growth discount rate used based aftertax rate derived capital asset pricing model using data capital markets including government twentyyear bonds weighted average tax rate used calculations corresponding pretax discount rate diagnostics division divisions business areas cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition part goodwill ventana acquisition recorded monitored divisional level relates strategic development whole division meaningfully allocated divisions business areas therefore cashgenerating unit goodwill entire division recoverable amount used impairment testing based value use cash flow projections based recent business plans approved management business plans include managements latest estimates sales volume pricing well production operating costs assume significant changes organisation business plans projected five years valuations include terminal value beyond years assuming growth discount rate used based aftertax rate derived capital asset pricing model using data capital markets including government twentyyear bonds weighted average tax rate used calculations corresponding pretax discount rate sensitivity analysis management performed sensitivity analyses roche pharmaceuticals diagnostics division increased discount rate combined decreasing forecast cash flows chugai decreased publicly quoted share prices results sensitivity analyses demonstrated changes key assumptions would cause carrying value goodwill exceed recoverable amount december roche finance report notes roche group consolidated financial statements roche group intangible assets intangible assets movements carrying value assets millions chf product product intangibles marketing technology intangibles available intangibles intangibles use use use use total january cost accumulated amortisation impairment net book value year ended december january business combinations additions transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals chugai diagnostics total group year ended december january business combinations additions transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals chugai diagnostics total group roche finance report roche group notes roche group consolidated financial statements significant intangible assets december millions chf remaining operating segment net book value amortisation period product intangibles use intermune acquisition roche pharmaceuticals years tanox acquisition roche pharmaceuticals years corangeboehringer mannheim acquisition diagnostics years iquum acquisition diagnostics years product intangibles available use seragon acquisition roche pharmaceuticals na dutalys acquisition roche pharmaceuticals na cmi acquisition diagnostics na genia acquisition diagnostics na technology intangibles use santaris acquisition roche pharmaceuticals years classification amortisation impairment expenses millions chf amortisation impairment cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics total internally generated intangible assets group currently internally generated intangible assets development criteria recognition asset met intangible assets indefinite useful lives group currently intangible assets indefinite useful lives intangible assets available use mostly represent inprocess research development assets acquired either inlicensing arrangements business combinations separate purchases december approximately projects pharmaceuticals division known decision points within next twelve months certain circumstances could lead impairment due inherent uncertainties research development processes intangible assets available use particularly risk impairment project expected result commercialised product roche finance report notes roche group consolidated financial statements roche group intangible asset impairment impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment impairment charges pharmaceuticals division impairment charges totalling million swiss francs recorded related clinical data assessment one development project million swiss francs asset concerned yet amortised fully written decision stop development compound acquired part previous business combination million swiss francs asset concerned yet amortised fully written decision stop development compound alliance partner million swiss francs asset concerned yet amortised fully written reassessment two projects within hepatitis c virus hcv franchise million swiss francs mainly due negative outcome arbitration competitor assets concerned yet amortised fully written decision stop development one compound million swiss francs asset concerned yet amortised fully written decision stop one collaboration project alliance partner million swiss francs assets concerned yet amortised fully written diagnostics division impairment charges totalling million swiss francs recorded related tissue diagnostics product intangibles available use million swiss francs factors leading impairment reassessment late stage future product development returned predesign phase demonstrate feasibility quality improvement asset concerned yet use fully written tissue diagnostics product intangibles use million swiss francs factors leading impairment decrease forecasted cash flows following us reductions immunohistochemistry testing reimbursement laboratories increase assetspecific pretax discount rate used impairment testing compared assets concerned amortised written estimated recoverable value million swiss francs diabetes care technology intangibles use million swiss francs factors leading impairment decrease forecasted cash flows following change timelines future product development increase asset specific pre tax discount rate used impairment testing compared assets concerned amortised written estimated recoverable value million swiss francs impairment charges pharmaceuticals division impairment charges totalling million swiss francs recorded related portfolio reassessment within hepatitis c virus hcv franchise million swiss francs assets concerned yet amortised written recoverable value million swiss francs portfolio reassessment within cardiovascular metabolic diseases franchise million swiss francs asset concerned yet amortised fully written decision stop two collaboration projects alliance partners million swiss francs assets concerned amortised fully written decision stop development one compound alliance partner million swiss francs asset concerned yet amortised fully written diagnostics division impairment charges totalling million swiss francs recorded applied science business area reorganisation assets concerned yet amortised fully written roche finance report roche group notes roche group consolidated financial statements potential commitments alliance collaborations group party inlicensing similar arrangements alliance partners arrangements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration agreements groups current estimate future thirdparty commitments payments set table figures undiscounted riskadjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group may arise roche chugai businesses potential future thirdparty collaboration payments december millions chf pharmaceuticals diagnostics group within one year one two years two three years total inventories inventories millions chf raw materials supplies work process intermediates finished goods provision slowmoving obsolete inventory total inventories inventories expensed cost sales totalled billion swiss francs billion swiss francs inventory writedowns year resulted expense million swiss francs million swiss francs accounts receivable accounts receivable millions chf trade receivables notes receivable receivables allowances doubtful accounts chargebacks allowances total accounts receivable roche finance report notes roche group consolidated financial statements roche group allowances doubtful accounts movements recognised liability millions chf january additional allowances created unused amounts reversed utilised year currency translation effects december bad debt expense marketing distribution totalled million swiss francs credit million swiss francs marketable securities marketable securities millions chf availableforsale financial assets equity securities debt securities money market instruments time accounts three months investments total marketable securities marketable securities held fund management purposes primarily denominated swiss francs us dollars euros money market instruments contracted mature within one year december debt securities contracted maturity millions chf within one year one five years five years total debt securities cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents roche finance report roche group notes roche group consolidated financial statements noncurrent assets noncurrent assets millions chf availableforsale investments held fair value availableforsale investments held cost loans receivable longterm trade receivables restricted cash receivables total financial noncurrent assets longterm employee benefits assets total nonfinancial noncurrent assets associates total noncurrent assets availableforsale investments mainly equity investments private biotechnology companies kept part groups strategic alliance efforts unquoted equity investments classified availableforsale measured cost fair value measured reliably current assets current assets millions chf accrued interest income derivative financial instruments restricted cash receivables total financial current assets prepaid expenses taxes recoverable assets total nonfinancial current assets total current assets receivables mainly related royalty licensing income receivables roche finance report notes roche group consolidated financial statements roche group accounts payable accounts payable millions chf trade payables taxes payable dividends payable payables total accounts payable noncurrent liabilities noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities longterm liabilities mainly related accrued employee benefits current liabilities current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued chargebacks allowances accrued royalties commissions accrued liabilities total current liabilities roche finance report roche group notes roche group consolidated financial statements provisions contingent liabilities provisions movements recognised liabilities millions chf legal environmental restructuring employee provisions provisions provisions provisions provisions total year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies contingent consideration currency translation effects december current noncurrent december year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration currency translation effects december current noncurrent december expected outflow resources within one year one two years two three years three years december legal provisions legal provisions consist number separate legal matters including claims arising trade various group companies nature amounts timings outflows difficult predict legal expenses totalled million swiss francs million swiss francs reflect recent developments various legal matters details major legal cases outstanding disclosed roche finance report notes roche group consolidated financial statements roche group environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts timings outflows difficult predict significant provisions discounted time value money material significant provisions relate closure us site nutley new jersey estimated remediation costs landfill site near grenzach germany used manufacturing operations closed years ago restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group timings cash outflows reasonably certain provisions discounted time value money material matters pharmaceuticals division significant provisions relate specialty care field force restructuring across europe closure us site nutley new jersey global outsourcing clinical trial monitoring intermune integration diagnostics division significant provisions relate restructuring diabetes care applied science businesses employee provisions mostly relate certain employee benefit obligations sabbatical leave longservice benefits timings cash outflows reasonably estimated based past experience provisions timing cash outflows nature uncertain provisions relate items shown table provisions millions chf sales returns contingent consideration items total provisions contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimates future commitments payments given note roche finance report roche group notes roche group consolidated financial statements pharmaceuticals legal cases accutane hoffmannla roche inc hlr various roche affiliates named defendants numerous legal actions us elsewhere relating acne medication accutane litigation alleges accutane caused certain serious conditions including limited inflammatory bowel disease ibd birth defects psychiatric disorders since january approximately cases dismissed us december hlr defending approximately actions involving approximately plaintiffs brought various federal state courts throughout us personal injuries allegedly resulting use accutane actions allege ibd result accutane use hlr announced following reevaluation portfolio medicines available generic manufacturers rapidly declining brand sales us high costs personalinjury lawsuits continues defend vigorously decided immediately discontinue manufacture distribution product us actions pending federal court alleging ibd consolidated pretrial proceedings multidistrict litigation us district court middle district florida tampa division since july district court granted summary judgment favour hlr federal ibd cases proceeded since august rulings affirmed us court appeals eleventh circuit plaintiffs appealed multiple recently filed matters remain pending actions pending state court new jersey alleging ibd consolidated pretrial proceedings superior court new jersey law division atlantic county december juries superior court ruled favour plaintiff eight cases assessing compensatory damages totalling million us dollars eight cases ruled favour plaintiff superior court hlr process appealing four cases million us dollars four cases verdicts reversed favour hlr million us dollars additional trials may scheduled individual trial results depend variety factors including many unique particular case therefore trial results date may predictive future trial results group continues defend vigorously remaining personal injury cases claims avastinlucentis investigations february italian antitrust authority agcm announced investigation determine whether roche genentech novartis entered agreement restrict competition italian market drugs reference particular avastin marketed roche lucentis marketed novartis avastin lucentis two different drugs developed approved different therapeutic purposes contain different active pharmaceutical ingredients march agcm issued verdict alleges roche novartis colluded artificially differentiate avastin lucentis order foster sales lucentis italy agcm fined roche million euros novartis million euros roche appealed agcm verdict tribunale amministrativo regionale del lazio tar december tar upheld decision agcm roche strongly disagrees verdict tar appeal may italian ministry health notified roche spa intention seek damages related matter july roche paid million euros fine protest avoid additional penalty fees recorded expense within general administration fine related interest reimbursed roche wins case outcome matters determined time tarceva subpoena november genentech received subpoena us department justice doj requesting documents information related promotion tarceva prescription product initially approved treatment locally advanced metastatic nonsmall cell lung cancer failure least one prior chemotherapy regimen later approved additional indications genentech cooperating associated investigation civil criminal nature may government representatives presented first time governments civil liability theory specifically genentech allegedly participated offlabel promotion tarceva causing submission false claims reimbursement civil false claims act subsequently genentech expects continue meetings communications government representatives discuss companys governments respective views legal factual issues discuss whether negotiated mutuallyagreeable settlement possible q request government genentech made presentation regarding various reasons company believes government decline make criminal claim company number current andor former genentech employees received subpoenas grand jury testimony beginning january outcome matters determined time roche finance report notes roche group consolidated financial statements roche group rituxan arbitration october genentech biogen idec inc filed complaint california sanofiaventis deutschland gmbh sanofiaventis us llc sanofiaventis us inc sanofi seeking declaratory judgment certain genentech products including rituxan infringe sanofis us patent nos patents invalid sanofi alleged rituxan another genentech product infringe certain claims patents march district court ruled matter law genentech biogen idec infringe asserted patent claims may sanofi appealed courts noninfringement ruling appellate court affirmed district courts judgment patent infringement addition october sanofi affiliate hoechst gmbh hoechst filed icc international court arbitration paris request arbitration genentech relating terminated patentlicense agreement one hoechsts predecessors genentech pertained abovementioned patents related patents outside us hoechst sought payment patent license royalties sales certain genentech products including rituxan damages breach contract relief various arbitral awards september february arbitrator found genentech liable hoechst patentlicense royalties rituxan awarded royalties interest hoechst sought february group recorded back royalty expense million swiss francs net assumed reimbursement portion groups obligation copromotion partner us hoechst initiated proceedings us france germany seeking enforce arbitral awards october genentech paid awarded royalties interest hoechst protest genentech seeking annulment arbitral awards proceedings initiated court appeal paris hearing proceedings june september paris court appeal stayed annulment proceedings seek guidance eu court justice specific legal question raised genentech relating arbitral awards noncompliance eu competition laws november hoechst filed notices appeal french supreme court seeking review paris court appeals decision seek guidance eu court justice outcome matter determined time average wholesale prices litigation hlr roche laboratories inc rli along approximately brand generic pharmaceutical companies named defendants several legal actions us relating pricing pharmaceutical drugs state medicaid reimbursement primary allegation litigations pharmaceutical companies misrepresented otherwise reported inaccurate average wholesale prices awp andor wholesale acquisition costs wac drugs prices allegedly relied upon states calculating medicaid reimbursements entities retail pharmacies states respective attorney general seeking repayment amounts claim overreimbursed time period associated cases december hlr rli defending one awp action filed state new jersey hlr rli vigorously defending matter limited fact discovery remains outstanding briefing class certification postponed second half trial date set matter outcome matter determined time pdl litigation august pdl biopharma pdl filed complaint nevada genentech seeking judicial declaration concerning genentechs obligation pay royalties certain exus sales herceptin avastin xolair lucentis agreement parties september pdl filed first amended complaint asserting additional claims genentech including breach contract breach implied covenant good faith fair dealing pdl also asserted new claims roche novartis intentional interference contractual relations addition declaratory relief pdl sought monetary damages including compensatory liquidated damages november genentech roche filed motion dismiss failure state claim roche filed additional motion dismiss lack personal jurisdiction july court denied motions pdl settled claim novartis addition litigation pdl conducted royalty audit related sales avastin herceptin lucentis xolair raptiva years final audit report indicated pdls interpretation certain contract terms genentech owed pdl additional royalties audit period interpretation genentech may owed additional royalties years subsequent audit period group disputed pdls interpretation relevant contract terms june pdl filed demand arbitration related audit claims american arbitration association january parties agreed settlement resolved disputes settlement agreement pdl agreed dismiss claims genentech roche return genentech agreed pay pdl single fixed royalty rate end matters concluded roche finance report roche group notes roche group consolidated financial statements gsk litigation september glaxosmithkline llc gsk genentech filed patent lawsuits one another delaware california respectively lawsuits concerned gsks us patent nos gsk asserted claims genentech alleging infringement patents herceptin lucentis seeking compensatory damages lawsuit genentech seeking judicial declaration noninfringement invalidity patents june parties agreed dismiss california action without prejudice consolidated case proceeded delaware august delaware court issued claim construction order construing two terms patent july parties signed settlement agreement resolved disputes matters concluded boniva litigation hlr genentech various roche affiliates collectively roche named defendants numerous legal actions us canada relating postmenopausal osteoporosis medication boniva litigations plaintiffs allege boniva caused either osteonecrosis jaw atypical femoral fractures december roche defending approximately actions involving approximately plaintiffs brought federal state courts throughout us one action brought court queens bench province saskatchewan canada personal injuries allegedly resulting use boniva cases early discovery stages litigation individual trial results depend variety factors including many unique particular case roche vigorously defending matters outcome matters determined time ema investigation october european medicines agency ema announced would start infringement procedure investigate allegations regarding alleged breach medicines safety reporting obligations relation centrally authorised medicines november ema announced results pharmacovigilance risk assessment committee assessment roches medicines ema found impact regarding benefitrisk balance roches medicines confirmed benefitrisk profiles based available safety information ema health authorities confirmed medicines remain authorised without changes treatment advice patients healthcare professionals corrective preventative actions resulting inspections implemented reinspection authorities november led certain findings roche addressing april ema issued report european commission summarises emas findings relation investigation european commission decide whether matter pursued financial penalties imposed decision european commission matter still pending outcome matter determined time roche finance report notes roche group consolidated financial statements roche group debt debt movements carrying value recognised liabilities millions chf january proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt net gains losses redemption repurchase bonds notes loss major debt restructuring amortisation debt discount business combinations net foreign currency transaction gains losses currency translation effects december bonds notes commercial paper amounts due banks financial institutions finance lease obligations borrowings total debt longterm debt shortterm debt total debt pledges groups assets connection debt roche finance report roche group notes roche group consolidated financial statements bonds notes recognised liabilities effective interest rates bonds notes millions chf effective interest rate underlying including instrument hedging us dollardenominated notes fixed rate notes due march principal billion us dollars isin usual usaq notes due september principal billion us dollars isin usbc notes due march principal billion us dollars outstanding billion us dollars isin usuam usas notes due september principal billion us dollars isin usba notes due september principal billion us dollars isin usbb na notes due september principal billion us dollars isin usbe na notes due march principal billion us dollars outstanding billion us dollars isin usuan usau na notes due november principal billion us dollars isin usbh na us dollardenominated notes floating rate notes due september principal billion us dollars isin usbd na notes due september principal billion us dollars isin usaz na european medium term note programme fixed rate notes due march principal billion euros isin xs notes due march principal billion pounds sterling outstanding million pounds sterling isin xs notes due march principal billion euros outstanding billion euros isin xs notes due june principal billion euros isin xs na notes due march principal billion euros isin xs notes due august principal million pounds sterling outstanding million pounds sterling isin xs na swiss franc bonds floating rate notes due september principal billion swiss francs isin ch na swiss franc bonds fixed rate bonds due march principal billion swiss francs isin ch na bonds due september principal billion swiss francs isin ch bonds due september principal billion swiss francs isin ch na genentech senior notes senior notes due july principal billion us dollars isin usag na senior notes due july principal million us dollars outstanding million us dollars isin usac na total bonds notes roche finance report notes roche group consolidated financial statements roche group bonds notes maturity millions chf within one year one two years two three years three four years four five years five years total bonds notes unamortised discount included carrying value bonds notes millions chf us dollar notes euro notes swiss franc bonds pound sterling notes total unamortised discount issuance bonds notes intermune acquisition september group financed intermune acquisition see note combination groups funds debt securities commercial paper group raised net proceeds approximately billion swiss francs debt offering described newly issued debt senior unsecured guaranteed roche holding ltd september group completed offering us dollardenominated notes group received approximately billion swiss francs aggregate net proceeds issuance sale fixed floating notes terms proceeds notes follows issuance us dollardenominated notes principal amount net proceeds usd millions chf millions floating rate notes due floating rate notes due fixed rate notes due fixed rate notes due fixed rate notes due fixed rate notes due total major debt restructuring november group major debt restructuring related debt incurred connection genentech transaction see note group raised net proceeds approximately billion swiss francs debt offering described newly issued debt senior unsecured guaranteed roche holding ltd debt used repurchase million us dollars fixed rate genentech senior notes due july million us dollars fixed rate notes due march major debt restructuring resulted loss repurchase million swiss francs roche finance report roche group notes roche group consolidated financial statements november group completed offering us dollardenominated notes group received approximately billion swiss francs aggregate net proceeds issuance sale fixed notes terms proceeds notes follows issuance us dollardenominated notes principal amount net proceeds usd millions chf millions fixed rate notes due fixed rate notes due total issuance bonds notes group issue bonds notes redemption repurchase bonds notes partial repurchase pound sterlingdenominated notes february group completed tender offer repurchase million pounds sterling fixed rate notes due march cash outflow million swiss francs plus accrued interest loss repurchase million swiss francs effective interest rate notes partial redemption us dollardenominated notes december group resolved exercise option call early partial redemption us dollardenominated fixed rate notes due march march group redeemed outstanding principal million us dollars amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal cash outflow million swiss francs plus accrued interest additional million swiss francs loss recorded redemption effective interest rate notes june group resolved exercise option call early partial redemption us dollardenominated fixed rate notes due march august group redeemed outstanding principal million us dollars amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal cash outflow million swiss francs plus accrued interest loss redemption million swiss francs effective interest rate notes november group completed tender offer repurchase million us dollars fixed rate notes due march cash outflow million swiss francs plus accrued interest loss repurchase million swiss francs effective interest rate notes partial repurchase genentech senior notes november group completed tender offer repurchase million us dollars fixed rate senior notes due july cash outflow million swiss francs plus accrued interest loss repurchase million swiss francs effective interest rate notes early redemption us dollardenominated notes december group resolved exercise option call early partial redemption us dollardenominated fixed rate notes due march group redeem outstanding principal million us dollars march amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal cash outflow approximately million us dollars plus accrued interest expected redemption group revised carrying value notes take account changes amounts timings estimated cash flows revised carrying value notes december million us dollars million swiss francs increase carrying value million us dollars million swiss francs recorded within financing costs see note loss redemption effective interest rate notes roche finance report notes roche group consolidated financial statements roche group redemption repurchase bonds notes group redeemed billion euros notes billion swiss francs bonds due dates completed early redemption billion us dollars notes cash flows issuance redemption repurchase bonds notes cash inflows issuance bonds notes millions chf us dollardenominated bonds total cash inflows issuance bonds notes cash outflows redemption repurchase bonds notes millions chf european medium term note programme eurodenominated notes european medium term note programme pound sterlingdenominated notes us dollardenominated notes swiss francdenominated bonds total cash outflows redemption repurchase bonds notes commercial paper roche holdings inc commercial paper program roche holdings inc established commercial paper program issue billion us dollars unsecured commercial paper notes guaranteed roche holding ltd committed credit line billion euros available backstop line maturity notes program exceed days date issuance december unsecured commercial paper notes principal amount billion us dollars average interest rate outstanding movements commercial paper obligations millions chf january net cash proceeds payments currency translation effects december amounts due banks financial institutions amounts denominated various currencies notably chinese renminbi argentine pesos average interest rate amounts outstanding million swiss francs december million swiss francs due within one year roche finance report roche group notes roche group consolidated financial statements equity attributable roche shareholders changes equity attributable roche shareholders millions chf reserves retained share capital earnings fair value hedging translation total year ended december january net income recognised income statement availableforsale investments fair value gains losses taken equity transferred income statement income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity december entire amount transferred income statement reported financial income expense roche finance report notes roche group consolidated financial statements roche group changes equity attributable roche shareholders millions chf reserves retained share capital earnings fair value hedging translation total year ended december january net income recognised income statement availableforsale investments fair value gains losses taken equity transferred income statement income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests december entire amount transferred income statement reported financial income expense genentech transaction group completed purchase noncontrolling interests genentech effective march based international accounting standard separate financial statements ias consistent international financial reporting standard consolidated financial statements ifrs adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group time reduced billion swiss francs billion swiss francs allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacted groups net equity effect groups business dividend policy roche finance report roche group notes roche group consolidated financial statements share capital december authorised issued share capital roche holding ltd groups parent company consisted million shares nominal value swiss franc preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares march shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition shareholder group pooled voting rights holds shares corresponding shares issued figure include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool described note based information supplied group novartis ltd basel affiliates participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends march shareholders approved distribution dividend swiss francs per share nonvoting equity security swiss francs respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs million swiss francs recorded retained earnings board directors proposed dividends business year swiss francs per share nonvoting equity security approved would result total distribution shareholders million swiss francs subject approval annual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities millions millions shares nonvoting equity securities derivative instruments total equity instruments recorded within equity original purchase cost december fair value shares billion swiss francs nonvoting equity securities billion swiss francs equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note roche finance report notes roche group consolidated financial statements roche group reserves fair value reserve fair value reserve represents cumulative net change fair value availableforsale financial assets asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs chugai effective october roche group chugai completed alliance create leading researchdriven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai consolidated subsidiary chugai fully consolidated subsidiary group based groups interest chugai december roche relationship chugai founded basic alliance licensing research collaboration agreements common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements accordance international financial reporting standards ifrs filed quarterly basis tokyo stock exchange due certain consolidation entries minor differences chugais standalone ifrs results results chugai consolidated roche group accordance ifrs financial information chugai summarised financial information millions chf income statement sales royalties operating income total revenues operating profit balance sheet noncurrent assets current assets noncurrent liabilities current liabilities total net assets cash flows cash flows operating activities cash flows investing activities cash flows financing activities roche finance report roche group notes roche group consolidated financial statements dividends dividends distributed third parties holding chugai shares totalled million swiss francs million swiss francs recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany items roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai also right first refusal development marketing japan development compounds advanced roche rest world umbrella rights agreement excluding japan south korea signed may revised amended restated rest world umbrella rights agreement excluding japan south korea taiwan signed august agreement roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea taiwan agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result payments arms length basis roche chugai following matters upfront payments right first refusal license product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements arms length basis research collaboration agreements roche chugai entered research collaboration agreements areas small molecule synthetic drug research biotechnologybased drug discovery roche finance report notes roche group consolidated financial statements roche group noncontrolling interests changes equity attributable noncontrolling interests millions chf january net income recognised income statement chugai noncontrolling interests total net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans comprehensive income net tax total comprehensive income dividends noncontrolling shareholders chugai noncontrolling interests equity compensation plans net transactions equity changes noncontrolling interests equity contribution noncontrolling interests december chugai noncontrolling interests total noncontrolling interests employee benefits employee remuneration millions chf wages salaries social security costs defined contribution plans operating expenses defined benefit plans equity compensation plans termination costs employee benefits employee remuneration included operating results net interest cost defined benefit plans total employee remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits roche finance report roche group notes roche group consolidated financial statements pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees time ensuring various plans appropriately financed managing potential impacts groups longterm financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements market practice countries employees employed postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans defined contribution plans defined contribution plans funded payments employees group funds administered third parties groups expenses plans million swiss francs million swiss francs assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions groups major defined contribution plans us notably us roche k savings plan defined benefit plans plans usually established trusts independent group funded payments group companies employees cases notably major defined benefit plans germany plans unfunded group pays pensions retired employees directly financial resources plans usually governed senior governing body board trustees typically composed employee employer representatives funding plans determined local regulations using independent actuarial valuations separate independent actuarial valuations together semiannual update prepared accordance requirements ias use groups financial statements groups major pension plans located switzerland us germany total account groups defined benefit obligation pension plans switzerland current pension arrangements employees switzerland made plans governed swiss federal occupational old age survivors disability pension act bvg groups pension plans administered separate legal foundations funded regular employee company contributions final benefit contributionbased certain minimum guarantees due minimum guarantees swiss plans treated defined benefit plans purposes ifrs financial statements although many characteristics defined contribution plans underfunding may remedied various measures increasing employee company contributions lowering interest rate retirement account balances reducing prospective benefits suspension early withdrawal facility past service costs include million swiss francs income recorded respect changes groups pension plans switzerland change represents adoption lower conversion rates determines annuity normal retirement age pension plans us groups major defined benefit plans us closed new members since new employees us join defined contribution plan largest remaining defined benefit plans funded pension plans including separate plans originating nutley palo alto indianapolis sites together smaller unfunded supplementary retirement plans benefits based highest average annual rate earnings specified period length employment plans noncontributory employees group making periodic payments plans payments made group million us dollars million us dollars underfunding would normally remedied additional company contributions us pension plans made offer deferred vested members settle defined benefit obligation lump sum payment total lump sum payment made defined benefit assets million us dollars million swiss francs settled obligation million us dollars million swiss francs led gain million us dollars million swiss francs included settlement gain roche finance report notes roche group consolidated financial statements roche group pension plans germany groups major pension arrangements germany governed occupational pensions act betravg plans unfunded group pays pensions retired employees directly financial resources plans noncontributory employees benefits based final salary length employment plans closed new members since replaced new plan funded regular employee company contributions administered contractual trust agreement final benefit contributionbased minimum guarantee due minimum guarantee plan treated defined benefit plan purposes ifrs financial statements although many characteristics defined contribution plan past service costs include million swiss francs income recorded respect changes groups german pension plans change represents adoption increase normal retirement age pension plans rest world represent approximately groups defined benefit obligation consist number smaller plans various countries largest pension plans chugai independently managed chugai main pension plan united kingdom chugai plans fully described chugais ifrs financial statements uk pension plan funded regular employee company contributions benefits based final salary length employment plan closed new members since replaced defined contribution plan past service costs include million swiss francs income recorded respect changes groups uk pension plans reflects change indexation pension increases consumer price index instead previously used retail price index postemployment benefit opeb plans represent approximately groups defined benefit obligation consist mostly postretirement healthcare life insurance schemes mainly us plans mainly unfunded contributory employees group reimbursing retired employees directly financial resources groups major defined benefit opeb plans us closed new members since part costs plans reimbursable medicare prescription drug improvement modernization act statutory funding requirement plans group funding plans extent tax efficient payments made group plans none december ifrs funding status including reimbursement rights funded opeb plans us defined benefit plans income statement millions chf post post pension employment total pension employment total plans benefit plans expense plans benefit plans expense current service cost past service income cost settlement gain loss total operating expenses net interest cost defined benefit plans total expense recognised income statement funding status funding groups various defined benefit plans responsibility senior governing body board trustees sponsoring employer managed based local statutory valuations follow legislation requirements respective jurisdiction plan established qualified independent actuaries carry statutory actuarial valuations regular basis actuarial assumptions determining funding status statutory basis regularly assessed local senior governing body funding status closely monitored corporate level fair value plan assets increased due favourable market conditions lower discount rates compared resulted increase overall defined benefit obligation result ifrs funded status funded defined benefit plans decreased reimbursement rights linked postemployment medical plans us represent expected reimbursement medical expenditure provided medicare prescription drug improvement modernization act roche finance report roche group notes roche group consolidated financial statements defined benefit plans funding status millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability reported balance sheet defined benefit plan assets defined benefit plan liabilities plan assets responsibility investment strategies funded plans senior governance body board trustees asset liability studies performed regularly major pension plans studies examine obligations postretirement benefit plans evaluate various investment strategies respect key financial measures expected returns expected risks expected contributions expected funded status plan interdependent way goal assetliability study select appropriate asset allocation funds held within plan investment strategy developed optimise expected returns manage risks contain fluctuations statutory funded status assetliability studies include strategies match cash flows assets plan obligations group currently use annuities longevity swaps manage longevity risk plan assets managed using internal external asset managers actual performance continually monitored pension fund governance bodies well closely monitored corporate level financial statements difference interest income actual return plan assets remeasurement recorded directly comprehensive income actual return plan assets gain million swiss francs gain million swiss francs recognition pension assets limited present value economic benefits available refunds plans reductions future contributions plans defined benefit plans fair value plan assets reimbursement rights millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january interest income plan assets remeasurements plan assets currency translation effects employer contributions employee contributions benefits paid funded plans benefits paid settlements administration costs december roche finance report notes roche group consolidated financial statements roche group defined benefit plans composition plan assets millions chf equity securities debt securities property cash money market instruments investments december assets invested variety different classes order maintain balance risk return follows equity debt securities mainly quoted market prices level fair value hierarchy property mainly private commercial property funds mainly observable inputs level fair value hierarchy cash money market instruments mainly invested financial institutions credit rating lower investments mainly consist alternatives mortgages commodities insurance contracts used risk management purposes mainly observable inputs level fair value hierarchy unobservable inputs level fair value hierarchy included within fair value plan assets groups shares nonvoting securities fair value million swiss francs million swiss francs debt instruments issued group fair value million swiss francs million swiss francs defined benefit obligation defined benefit obligation calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth mortality rates present value defined benefit obligation determined discounting estimated future cash outflows using interest rates highquality corporate bonds government bonds countries deep market corporate bonds corporate government bonds denominated currency benefits paid maturity terms approximating terms related pension obligation groups final salarybased defined benefit pension plans us germany united kingdom closed new participants active employees members pension plans time closed new participants continue accrue benefits final salarybased defined benefit pension plans new employees us uk join groups defined contribution plans new employees germany join contributionbased plan minimum guarantee defined benefit pension plans switzerland final benefit contributionbased minimum guarantee remain open new employees result proportion defined benefit obligation relates closed plans expected decrease future roche finance report roche group notes roche group consolidated financial statements defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january current service cost interest cost remeasurements demographic assumptions financial assumptions experience adjustments currency translation effects employee contributions benefits paid funded plans benefits paid unfunded plans benefits paid settlements past service income cost settlement gain loss december composition plan active members deferred vested members retired members december plans geography switzerland united states germany rest world december duration years actuarial assumptions actuarial assumptions used financial statements based requirements set ias employee benefits unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management based advice actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters interest rates salary benefit levels inflation rates costs medical benefits actuarial assumptions vary based upon local economic social conditions actuarial assumptions used various statutory valuations may differ based local legal regulatory requirements roche finance report notes roche group consolidated financial statements roche group demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes increases longevity rates employee turnover disability early retirement based historical behaviour within group companies average life expectancy assumed individual age follows defined benefit plans average life expectancy major schemes years male female country mortality table switzerland bvg generational tables united states rp projected mp germany heubeck tables g us mortality tables updated increased overall us defined benefit obligation million swiss francs financial assumptions based market expectations period obligations settled assumptions used actuarial valuations shown defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates salary increases expected rates pension increases expected inflation rates immediate medical cost trend rate ultimate medical cost trend rate discount rates determined reference interest rates highquality corporate bonds government bonds countries deep market corporate bonds expected rates salary increases based expected inflation rates adjustment reflect groups latest expectation longterm real salary increases expected rates pension increases generally linked expected inflation rate expected inflation rates derived looking level inflation implied financial markets conjunction economists price inflation forecasts historic price inflation well economic variables circumstances medical cost trend rates take account benefits set plan terms expected future changes medical costs since groups major postemployment medical plans us employees rates driven developments us sensitivity analysis measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions following table summarises impact change assumptions present value defined benefit obligation defined benefit plans sensitivity defined benefit obligation actuarial assumptions millions chf year increase life expectancy discount rates increase decrease expected inflation rates increase decrease immediate medical cost trend rate increase decrease sensitivity analysis considers change one assumption time leaving assumptions unchanged approach shows isolated effect changing one individual assumption take account assumptions related method used carry sensitivity analysis prior year roche finance report roche group notes roche group consolidated financial statements cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions net reimbursements funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately million swiss francs includes estimated million swiss francs additional contributions mostly related us defined benefit plans benefits paid unfunded plans estimated approximately million swiss francs mostly relate german defined benefit plans equity compensation plans group operates several equity compensation plans including separate plans chugai ifrs sharebased payment requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expenses equity compensation plans roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan roche connect roche option plan bonus stock awards chugai stock acquisition rights total operating expenses equitysettled cashsettled roche finance report notes roche group consolidated financial statements roche group cash inflow outflow equity compensation plans millions chf roche option plan exercises chugai stock acquisition rights exercises roche connect costs transactions equity total cash inflow outflow equitysettled equity compensation plans net transactions equity net cash outflow transactions equity mainly arises sales purchases equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note equity compensation plans roche stocksettled stock appreciation rights group issues stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive nonvoting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date roche ssar plan million ssars available issuance tenyear period rights nontradable equitysettled awards sevenyear duration vest phased basis three years roche ssars movement number rights outstanding weighted average weighted average number rights exercise price number rights exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable number weighted average weighted average number weighted average outstanding years remaining exercise price exercisable exercise price year grant thousands contractual life chf thousands chf total roche restricted stock unit plan group issues restricted stock units rsus awards certain directors management employees selected discretion group rsus nontradable represent right receive nonvoting equity securities vest threeyear period subject performance conditions currently performance conditions outstanding rsus december roche rsu plan million nonvoting equity securities available issuance tenyear period roche rsu plan also includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award granted roche finance report roche group notes roche group consolidated financial statements roche rsus movement number awards outstanding number awards number awards thousands thousands outstanding january granted forfeited transferred participants outstanding december vested transferable roche performance share plan group offers future nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers nontradable equitysettled awards programme currently operates annual threeyear cycles roche psp plan includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award granted amount nonvoting equity securities allocated depend upon individuals salary level achievement performance targets linked groups total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors award result zero two nonvoting equity securities value adjustment depending upon achievement performance targets roche performance share plan terms outstanding awards december number awards outstanding thousands vesting period years years years allocated recipients feb feb feb fair value per unit grant chf total fair value grant chf millions roche connect programme enables employees worldwide except us certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held million nonvoting equity securities million cost plan million swiss francs million swiss francs roche option plan programme used countries ssars used awards plan give employees right purchase nonvoting equity securities exercise price specified grant date options nontradable equity settled awards sevenyear duration vest phased basis three years subject continued employment roche option plan movement number options outstanding weighted average weighted average number options exercise price number options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche finance report notes roche group consolidated financial statements roche group roche option plan terms options outstanding december options outstanding options exercisable weighted average weighted average weighted average number outstanding years remaining exercise price number exercisable exercise price year grant thousands contractual life chf thousands chf total weighted average share price roche nonvoting equity securities year swiss francs swiss francs bonus stock awards chairman board directors dr humer chief executive officer granted bonus stock awards lieu cashsettled bonus financial year issued end april number awards fair value per award calculated grant date chugai stock acquisition rights chugai stock acquisition right programmes total fair value rights issued equivalent million swiss francs million swiss francs rights issued employees directors chugai rights nontradable equitysettled awards tenyear duration vest two years right entitles holder purchase chugai shares specified exercise price addition rights issued directors chugai thirtyyear duration vest upon holders retirement director chugai right entitles holder purchase chugai shares exercise price japanese yen fair value measurement inputs used measurement fair values grant date equity compensation plans follows fair value measurement roche stocksettled roche stock appreciation roche restricted performance share roche option rights stock unit plan plan plan progressively cliff vesting cliff vesting progressively vesting period years years years years contractual life years na na years number granted year thousands weighted average fair value chf model used binomial market price monte carlo b binomial inputs option pricing model share price grant date chf exercise price chf expected volatility c na na expected dividend yield na na early exercise factor na na expected exit rate na na fair value roche rsus equivalent share price date grant b input parameters covariance matrix roche individual companies peer group based threeyear history riskfree rate minus valuation takes account defined rank performance structure determines payout plan c volatility determined primarily reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour roche finance report roche group notes roche group consolidated financial statements earnings per share nonvoting equity security basic earnings per share nonvoting equity security net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number shares nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security net income attributable roche shareholders chf millions increase noncontrolling interests share group net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf roche finance report notes roche group consolidated financial statements roche group statement cash flows cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics businesses calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown statement cash flows operating cash flows also include income taxes paid activities cash generated operations millions chf net income add back nonoperating income expense financing costs financial income expense income taxes operating profit depreciation property plant equipment amortisation intangible assets impairment goodwill impairment intangible assets impairment reversal property plant equipment operating income expense defined benefit plans operating expense equitysettled equity compensation plans net income expense provisions bad debt reversal expense inventory writedowns net gain loss disposal products adjustments cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total cash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity roche finance report roche group notes roche group consolidated financial statements dividends paid millions chf dividends roche group shareholders dividends noncontrolling shareholders chugai dividends noncontrolling shareholders increase decrease dividends payable dividend withholding tax total significant noncash transactions significant noncash transactions none except contingent consideration arrangements arising business combinations see notes risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part business planning controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties financial risk management within group governed policies reviewed boards directors roche chugai appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits type authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche chugai credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying value groups financial assets accounts receivable december group trade receivables billion swiss francs billion swiss francs subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective trade receivables management maximise collection unpaid amounts roche finance report notes roche group consolidated financial statements roche group december groups combined trade receivables balance three us national wholesale distributors amerisourcebergen corp mckesson corp cardinal health inc equivalent billion swiss francs representing groups consolidated trade receivables billion swiss francs representing significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral held trade receivables none since financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries trade receivables billion swiss francs billion swiss francs public customers countries december trade receivables italy spain greece portugal decreased due improved collections compared group uses different measures improve collections countries including intense communication customers factoring negotiations payments plans charging interest late payments legal action nature geographic location counterparties accounts receivable overdue impaired shown table include balances us national wholesalers southern europe public customers described accounts receivable overdue nature geographical location counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland europe north america latin america japan asia australia oceania rest world total ageing accounts receivable impaired shown table ageing accounts receivable impaired millions chf neither overdue impaired overdue month overdue months overdue months overdue months overdue year total accounts receivable cash marketable securities december group cash marketable securities billion swiss francs billion swiss francs subject policy restricting exposures highquality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly investments marketable securities entered basis guidelines regard liquidity quality maximum amount general rule group invests highquality securities adequate liquidity cash shortterm time deposits subject rules limit groups exposure individual financial institutions roche finance report roche group notes roche group consolidated financial statements rating analysis cash fixed income marketable securities market values mchf total mchf total aaarange aarange arange bbbrange bbbrange unrated total master netting agreements group enters derivative transactions collateral agreements international swaps derivatives association isda master netting agreements respective counterparties order mitigate counterparty risk agreements amounts owed counterparty single day respect transactions outstanding currency aggregated single net amount payable one party isda agreements meet criteria offsetting balance sheet group currently enforceable right offset recognised amounts right offset enforceable occurrence future events default credit events contract terms december significant financial assets whose terms renegotiated none impairment losses total impairment losses availableforsale financial assets amounted million swiss francs million swiss francs liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time roche chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements december group unused committed credit lines various financial institutions totalling billion swiss francs billion swiss francs billion swiss francs serve backstop line commercial paper programme remaining undiscounted cash flow contractual maturities financial liabilities including estimated interest payments shown table contractual maturities financial liabilities millions chf carrying less value total year years years years year ended december debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities year ended december debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities roche finance report notes roche group consolidated financial statements roche group market risk market risk arises changing market prices mainly foreign exchange rates interest rates groups financial assets financial liabilities affect groups financial result equity valueatrisk group uses valueatrisk var measure impact market risk financial instruments var indicates value range within given financial instrument fluctuate preset probability result movements market prices var calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period trading days past ten years holding period reflects time required change corresponding risk exposure deemed appropriate actual future gains losses associated treasury activities may differ materially var analyses due inherent limitations associated predicting timing amount changes interest rates foreign exchange rates equity investment prices particularly periods high market volatilities furthermore var include effect changes credit spreads market risk financial instruments millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component decreased mainly due ageing restructuring debt environment largely stable rates major economies foreign exchange component decreased due favourable exposure mix price component arises mainly movements equity security prices increased group held equity securities foreign exchange risk group uses swiss franc reporting currency result exposed movements foreign currencies mainly us dollar japanese yen euro objective groups foreign exchange risk management activities preserve economic value current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group uses forward contracts foreign exchange options crosscurrency swaps hedge transaction exposures application instruments intends continuously lock favourable developments foreign exchange rates thereby reducing exposure potential future movements rates interest rate risk group mainly raises debt fixed rate basis bonds notes group exposed movements interest rates mainly us dollar swiss franc eurodenominated floating rate financial instruments primary objective groups interest rate management protect net interest result group may use forward contracts options swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposures interest rate hedging group entered following interest rate hedging contracts interest rate swap contracts combined notional principal million us dollars swapped fixed interest rate effective floating interest rate months usdlibor plus average spread maturity swaps september interest rate swap contracts combined notional principal billion swiss francs swapped fixed interest rate effective floating interest rate months usdlibor plus average spread maturity swaps september roche finance report roche group notes roche group consolidated financial statements price risk price risk arises mainly movements prices equity securities group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments capital management group defines capital manages groups total capitalisation sum debt plus equity including non controlling interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events capitalisation reported senior management part groups regular internal management reporting shown table capital millions chf capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity total debt capitalisation groups net equity significantly impacted genentech transaction see note group subject regulatory capital adequacy requirements known financial services industry group majority shareholding chugai see note chugai public company objectives policies processes managing capital determined local management roche finance report notes roche group consolidated financial statements roche group financial instrument accounting classifications fair values fair values financial assets liabilities together carrying value shown consolidated balance sheet follows carrying value fair value financial instruments millions chf fair value total available hedging fair value loans financial carrying forsale instruments designated receivables liabilities value fair value year ended december noncurrent assets availableforsale investments financial noncurrent assets accounts receivable marketable securities cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities year ended december noncurrent assets availableforsale investments financial noncurrent assets accounts receivable marketable securities cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities fair value bonds notes level calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods roche finance report roche group notes roche group consolidated financial statements fair value hierarchy table analyses financial instruments carried fair value valuation method different levels defined follows level quoted prices unadjusted active markets identical assets liabilities level observable inputs quoted prices active markets identical assets liabilities level unobservable inputs fair value hierarchy financial instruments millions chf level level level total year ended december marketable securities equity securities debt securities money market instruments time accounts three months derivative financial instruments availableforsale investments held fair value financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value year ended december marketable securities equity securities debt securities money market instruments time accounts three months derivative financial instruments availableforsale investments held fair value financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value level financial assets consist treasury bills bonds quoted shares level financial assets consist primarily commercial paper certificates deposit derivative financial instruments group determines level fair values using following valuation techniques marketable securities derivative financial instruments based valuation models use observable market data interest rates yield curves foreign exchange rates implied volatilities similar instruments measurement date availableforsale investments using valuation model derived recently published observable financial prices group recognises transfers levels fair value hierarchy end reporting period transfer occurred significant transfers level level vice versa year none roche finance report notes roche group consolidated financial statements roche group level fair values details determination level fair value measurements transfer level fair value hierarchy set contingent consideration arrangements millions chf january arising business combinations acquired business combinations total unrealised gains losses included income statement unused amounts reversed additional amount created discount unwind total gains losses included comprehensive income currency translation effects transfers level utilised december contingent consideration arrangements group party certain contingent consideration arrangements arising business combinations fair values determined considering expected payments discounted present value using riskadjusted average discount rate expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario significant unobservable inputs forecast sales performance criteria riskadjusted discount rate estimated fair value would increase forecast sales performance criteria rate higher riskadjusted discount rate lower december total payments contingent consideration arrangements could million swiss francs million swiss francs significant contingent consideration arrangements relate seragon santaris dutalys iquum genia cmi acquisitions derivative financial instruments group entered various currency swaps certain nonus dollar debt instruments cash collateral agreements entered counterparties currency swaps mitigate counterparty risk following table sets carrying value derivative financial instruments amounts subject master netting agreements derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts crosscurrency swaps interest rate derivatives swaps derivatives carrying value derivative financial instruments derivatives subject master netting agreements collateral arrangements net amount roche finance report roche group notes roche group consolidated financial statements collateral arrangements fair value currency swaps decreased mainly due weaker euro compared us dollar result cash delivered group counterparties movements cash collateral receivable accrued liability millions chf january net cash delivered group december hedge accounting december group following cash flow hedges fair value hedges designated qualifying hedge relationship cash flow hedges group entered crosscurrency swaps hedge foreign exchange interest rate risk bonds notes issued group denominated euros sterling december instruments recorded fair value assets million swiss francs liabilities million swiss francs assets million swiss francs ineffective portion chugai entered foreign exchange forward contracts hedge part foreign translation exposure swiss francs us dollars december instruments recorded fair value assets million swiss francs assets million swiss francs ineffective portion expected undiscounted cash flows qualifying cash flow hedges including interest payments duration derivative contract final settlement maturity shown table expected cash flows qualifying cash flow hedges millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow undiscounted cash flows table affect profit loss shown include interest payments duration derivative contract include final settlement maturity expected cash flows qualifying cash flow hedges impact profit loss millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow changes hedging reserve within equity shown note fair value hedges group entered interest rate swaps hedge fixedterm debt instruments december instruments recorded fair value liabilities million swiss francs million swiss francs fair value assets million swiss francs million swiss francs gain million swiss francs recorded interest rate swaps loss million swiss francs fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments roche finance report notes roche group consolidated financial statements roche group group equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part exposure group entered forward contracts designated qualify fair value hedges december instruments recorded fair value liabilities million swiss francs liabilities million swiss francs loss million swiss francs recorded forward contracts loss million swiss francs result forward contracts offset changes fair value hedged equity investments held within marketable securities see note net investment hedges group net investment hedges related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool mr andr hoffmann dr andreas oeri members board directors roche holding ltd mr hoffmann received remuneration totalling swiss francs swiss francs dr oeri received remuneration totalling swiss francs swiss francs transactions group individual members shareholder group subsidiaries associates listing major group subsidiaries associates included note transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associates key management personnel total remuneration key management personnel million swiss francs million swiss francs members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees dr franz dr humer members corporate executive committee roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members corporate executive committee members corporate executive committee also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note new members corporate executive committee included table full calendar year joined cec similarly members corporate executive committee retiring part way year included full calendar year left cec roche finance report roche group notes roche group consolidated financial statements remuneration members board directors corporate executive committee millions chf salaries including cashsettled bonus bonus stock awards social security costs pensions postemployment benefits equity compensation plans board fees employee benefits total purposes remuneration disclosures values equity compensation plans including bonus stock awards calculated based fair value used note represent cost group awards grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions detailed disclosures regarding executive remuneration required swiss law included remuneration report included annual report pages disclosures values equity compensation plans including bonus stock awards represent fair value employee receives taking account preliminary assessment completed performance conditions fair values shown table reconciles disclosures required swiss law related party disclosures key management personnel reconciliation executive remuneration disclosures required swiss law millions chf total remuneration members board directors corporate executive committee ifrs basis see table deduct bonus stock awards ifrs basis equity compensation plans ifrs basis add back bonus stock awards swiss legal basis equity compensation plans swiss legal basis total remuneration members board directors corporate executive committee swiss legal basis including social security costs board directors annual report corporate executive committee annual report bonus stock awards chairman board directors dr humer chief executive officer granted bonus stock awards lieu cashsettled bonus financial year issued end april number awards fair value per award calculated grant date roche finance report notes roche group consolidated financial statements roche group equity compensation plans members corporate executive committee received equity compensation shown following tables number rights options awards granted members corporate executive committee roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan contributions paid dr humer members corporate executive committee millions chf roche connect transactions former members board directors corporate executive committee pensions totalling million swiss francs paid group former corporate executive committee members million swiss francs subsequent retirement member board directors dr humer received million swiss francs advisory capacity chairman board defined benefit plans transactions group various defined benefit plans employees group described note subsidiaries associates listed companies share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange six swiss exchange zurich valor share valor genussschein isin share ch isin genussschein ch market capitalisation chf japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy nonlisted companies share capital equity interest country company city millions algeria roche algrie spa bab ezzouar dzd argentina productos roche sa qumica e industrial buenos aires ars vanguardia en productos farmacuticos vanprofarma sa buenos aires ars australia roche diabetes care australia pty limited bella vista aud roche diagnostics australia pty limited castle hill aud roche products pty limited dee aud austria dutalys gmbh vienna eur intermune austria gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostics gmbh vienna eur roche diagnostics graz gmbh graz eur visiomab gmbh vienna eur roche finance report roche group notes roche group consolidated financial statements share capital equity interest country company city millions azerbaijan roche azerbaijan llc baku azn bangladesh roche bangladesh limited dhaka bdt belarus fllc roche products limited minsk byr belgium nv roche sa brussels eur roche diagnostics belgium nv brussels eur bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd bosniaherzegovina roche ltd pharmaceutical company sarajevo bam brazil produtos roche qumicos e farmacuticos sa paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada chempharm limited toronto cad hoffmannla roche limited toronto cad intermune canada inc burlington cad sapac corporation ltd st john cad chile roche chile limitada santiago de chile clp china roche china holding ltd shanghai usd roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica roche servicios sa heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostics hvidovre dkk roche innovation center copenhagen hoersholm dkk dominican republic productos roche dominicana sa santo domingo dop ecuador roche ecuador sa quito usd el salvador productos roche el salvador sa san salvador svc egypt rodiagnostics egypt trading sae giza egp roche egypt llc cairo egp estonia roche eesti tallinn eur finland roche diagnostics oy espoo eur roche oy espoo eur france institut roche de recherche et mdecine translationnelle sas boulognebillancourt eur intermune france sas boulognebillancourt eur roche diabetes care france sas meylan eur roche diagnostics france sas meylan eur roche sas boulognebillancourt eur ventana medical systems sas illkirch eur georgia roche georgia llc tbilisi gel germany intermune deutschland gmbh berlin eur galenus mannheim gmbh mannheim eur galenus mannheim pharma gmbh mannheim eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen eur roche diabetes care gmbh mannheim eur roche diabetes care deutschland gmbh mannheim eur roche diagnostics deutschland gmbh mannheim eur roche diagnostics gmbh mannheim eur roche mtm laboratories ag heidelberg eur roche pharma ag grenzachwyhlen eur roche pvt gmbh waiblingen dem swisslab gmbh berlin eur verum diagnostica gmbh munich eur ghana roche products ghana limited accra ghs greece roche hellas sa athens eur roche diagnostics hellas sa athens eur guatemala productos roche guatemala sa guatemala gtq honduras productos roche honduras sa tegucigalpa hnl roche finance report notes roche group consolidated financial statements roche group share capital equity interest country company city millions hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostics india pvt ltd mumbai inr roche products india pvt ltd mumbai inr indonesia pt roche indonesia jakarta idr iran roche pars co ltd tehran irr ireland roche diabetes care limited irish branch dublin eur roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit ils roche pharmaceuticals israel ltd petach tikva ils italy intermune srl milan eur roche diagnostics spa milan eur roche spa milan eur ivory coast roche cte divoire sarl abidjan xof jordan f hoffmannla roche ltd jordan psc amman jod japan roche diagnostics kk tokyo jpy kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius ltl macedonia roche makedonija dooel skopje mkd malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd petaling jaya myr syntex pharmaceuticals sdn bhd kuala lumpur myr mauritius roche products mauritius limited quatre bornes mur mexico productos roche sa de cv mexico city mxn roche servicios de mxico sa de cv mexico city mxn moldova roche products limited srl chisinau mdl morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherlands intermune benelux bv nieuwegein eur roche diabetes care nederland bv almere eur roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics nz limited auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche products limited lagos ngn norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr palestine roche pharmaceuticals palestine ltd ramallah albireh usd panama productos roche panam sa panama city pab productos roche interamericana sa panama city usd roche products inc panama city usd syntex puerto rico inc panama city usd peru productos roche qumica farmacutica sa lima pen roche farma peru sa lima pen philippines roche philippines inc taguig city php poland roche diabetes care polska sp z oo warsaw pln roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diagnostics rus moscow rub roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diabetes care asia pacific pte ltd singapore sgd roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druzba doo ljubljana eur south africa roche products proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw roche finance report roche group notes roche group consolidated financial statements share capital equity interest country company city millions spain andreu roche sa madrid eur intermune spain sl madrid eur roche diagnostics sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sri lanka roche products colombo private limited colombo lkr sweden intermune nordics ab kista sek roche ab stockholm sek roche diagnostics scandinavia ab bromma sek switzerland f hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf intermune international ag muttenz chf intermune schweiz gmbh muttenz chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche diabetes care ltd rotkreuz chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah united arab emirates roche diagnostics middle east fzco dubai aed roche middle east fzco dubai aed united kingdom intermune bristol limited london gbp intermune holdings limited london gbp intermune uk limited london gbp intermune uk limited london gbp piramed limited welwyn garden city gbp roche diabetes care limited burgess hill gbp roche diagnostics ltd burgess hill gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp united states life sciences corporation branford usd anadys pharmaceuticals inc south san francisco usd bina technologies inc redwood city usd bioveris corporation indianapolis usd genentech inc south san francisco usd genentech usa inc south san francisco usd genia technologies corp mountain view usd hlr consumer health inc nutley usd hoffmannla roche inc nutley usd igen international inc pleasanton usd intermune inc wilmington usd iquum inc marlborough usd marcadia biotech inc nutley usd roche carolina inc florence usd roche diabetes care inc indianapolis usd roche diagnostics corporation indianapolis usd roche diagnostics hematology inc westborough usd roche diagnostics operations inc indianapolis usd roche health solutions inc fishers usd roche holdings inc south san francisco usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche tcrc inc new york usd seragon pharmaceuticals inc wilmington usd spring bioscience corp pleasanton usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch hamilton uyu venezuela productos roche sa caracas vef vietnam roche vietnam co ltd ho chi minh city usd share capital less local currency units roche finance report notes roche group consolidated financial statements roche group significant accounting policies consolidation policy subsidiaries companies including structured entities group control group controls entity group exposed rights variable returns involvement entity ability affect returns power entity companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control associates companies group exercises power exercise significant influence control accounted using equity method segment reporting purpose segment reporting groups corporate executive committee cec considered groups chief operating decision maker determination groups operating segments based organisation units information reported cec regular basis information provided used basis segment revenue profit disclosures reported note geographic analysis based location customers selected segment balance sheet information also routinely provided cec transfer prices operating segments set arms length basis operating assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt foreign currency translation annual financial statements presented swiss francs group companies use local currency functional currency certain group companies use currencies us dollars swiss francs euros functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity cases gains losses deferred comprehensive income upon consolidation assets liabilities group companies using functional currencies swiss francs translated swiss francs using yearend rates exchange income statement statement cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly comprehensive income roche finance report roche group notes roche group consolidated financial statements revenues sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates exclude value added taxes taxes directly linked sales revenues sale products recognised upon transfer customer significant risks rewards trade discounts cash discounts volume rebates recorded accrual basis consistent recognition related sales estimates expected sales returns chargebacks rebates including medicaid us similar rebates countries also deducted sales recorded accrued liabilities provisions deduction accounts receivable estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience circumstances level sales returns hence revenues reliably measured sales recognised right return expires generally upon prescription products patients revenues recorded earned services performed single transactions split separately identifiable components reflect substance transaction necessary conversely two transactions may considered together revenue recognition purposes commercial effect understood without reference series transactions whole cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered royalties alliance collaboration expenses including collaboration profitsharing arrangements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred research development internal research development activities expensed incurred following internal research costs incurred purpose gaining new scientific technical knowledge understanding internal development costs incurred application research findings knowledge plan develop new products commercial production development projects undertaken group subject technical regulatory uncertainties opinion management criteria capitalisation intangible assets met prior obtaining marketing approval regulatory authorities major markets postmarketing studies regulatory approval phase iv costs pharmaceuticals business generally involve safety surveillance ongoing technical support drug receives marketing approval sold may required regulatory authorities may undertaken safety commercial reasons costs postmarketing studies capitalised intangible assets opinion management generate separately identifiable incremental future economic benefits reliably measured acquired inprocess research development resources obtained inlicensing arrangements business combinations separate asset purchases capitalised intangible assets acquired asset must controlled group separately identifiable expected generate future economic benefits even uncertainty exists whether research development ultimately result marketable product consequently upfront milestone payments third parties pharmaceutical products compounds regulatory marketing approval recognised intangible assets assets acquired arrangements measured basis set intangible assets policy subsequent internal research development costs incurred post acquisition treated way internal research development costs research development embedded contracts strategic alliances group carefully assesses whether upfront milestone payments constitute funding research development work acquisition asset licensing milestone upfront receipts royalty income recognised accrual basis accordance substance respective licensing agreements collectability royalty amount reasonably assured royalties recognised revenue cash received certain group companies receive upfront milestone similar payments third parties relating sale licensing products technology revenue associated performance milestones recognised based achievement deliverables defined respective agreements upfront payments licence fees subsequent deliverables initially reported deferred income recognised income earned period development collaboration manufacturing obligation roche finance report notes roche group consolidated financial statements roche group employee benefits shortterm employee benefits include wages salaries social security contributions paid annual leave sick leave profit sharing bonuses nonmonetary benefits current employees costs recognised within operating results employee rendered associated service group recognises liability profit sharing bonuses contractually obliged past practice created constructive obligation longterm employee benefits include longservice sabbatical leave longservice benefits longterm disability benefits expected costs benefits accrued period employment changes carrying value longterm employee benefit liabilities recognised within operating results termination benefits payable employment terminated group normal retirement date whenever employee accepts voluntary redundancy exchange benefits termination costs recognised earlier group longer withdraw offer benefits group recognises related restructuring costs pensions postemployment benefits defined contribution plans group contributions recognised within operating results employee rendered associated service prepaid contributions recognised asset extent cash refund reduction future payments available defined benefit plans liability recognised balance sheet present value defined benefit obligation less fair value plan assets changes net defined benefit liability recognised occur follows recognised income statement current service costs charged appropriate income statement heading within operating results past service costs including curtailment gains losses recognised immediately general administration within operating results settlement gains losses recognised general administration within operating results net interest net defined benefit liability recognised financing costs recognised comprehensive income actuarial gains losses arising experience adjustments difference previous assumptions actually occurred changes actuarial assumptions return plan assets excluding amounts included net interest net defined benefit liability change limit recognition plan assets excluding amounts included net interest net defined benefit liability net interest net defined benefit liability comprised interest income plan assets interest cost defined benefit obligation interest effect limit recognition pension assets net interest calculated using discount rate used calculating defined benefit obligation applied net defined liability start period taking account changes contribution benefit payments pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan equity compensation plans fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded expense subsequent cash flows exercises vested awards recorded changes equity roche finance report roche group notes roche group consolidated financial statements property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful lives assets regularly reviewed necessary future depreciation charges accelerated repairs maintenance costs expensed incurred leases group lessee finance leases exist substantially risks rewards ownership transferred group finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt finance lease assets depreciated shorter lease term useful life interest element lease payment charged income lease term based effective interest rate method operating leases exist substantially risks rewards ownership transferred group payments made operating leases charged income straightline basis period lease group lessor certain assets mainly diagnostics instruments leased third parties finance operating lease arrangements finance lease assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method operating lease assets reported within property plant equipment lease income operating leases recognised lease term straightline basis business combinations business combinations accounted using acquisition method accounting date acquisition group initially recognises fair value identifiable assets acquired liabilities assumed noncontrolling interest acquired business consideration transferred measured fair value date acquisition group acquire ownership acquired business noncontrolling interests recorded either fair value proportion fair value acquired net assets attributable noncontrolling interest directly attributable acquisitionrelated costs expensed incurred within general administration expenses goodwill goodwill arises business combination excess consideration transferred acquire business underlying fair value net identified assets acquired goodwill amortised tested impairment least annually upon occurrence indication impairment roche finance report notes roche group consolidated financial statements roche group intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination initially recorded fair value available use intangible assets amortised straight line basis useful lives intangible assets reviewed impairment reporting date estimated useful life lower legal duration economic useful life estimated useful lives intangible assets regularly reviewed estimated useful lives major classes amortisable intangible assets follows product intangibles use years marketing intangibles use years technology intangibles use years impairment property plant equipment intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs sell value use less carrying value carrying value reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally five year period extrapolating projections subsequent years discounted using appropriate longterm interest rate impairment loss arises useful life asset reviewed necessary future depreciationamortisation charge accelerated amount impairment loss subsequently decreases decrease related objectively event occurring impairment recognised previously recognised impairment loss reversed income statement impairment reversal impairment goodwill goodwill assessed impairment reporting date additionally tested annually impairment goodwill allocated cashgenerating units recoverable amount cashgenerating unit higher fair value less costs sell value use less carrying value carrying value goodwill reduced recoverable amount reduction reported income statement impairment loss acquired business included within cashgenerating unit permanently ceases operate treated disposal business separately identifiable goodwill generated initial acquisition business factors made goodwill entirely unrelated continuing operations cashgenerating unit goodwill deemed disposed fully impaired impairment testing methodology described note inventories inventories stated lower cost net realisable value cost finished goods work process includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses accounts receivable accounts receivable carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances allowance doubtful accounts recorded objective evidence group able collect amounts due estimates based specific indicators ageing customer balances specific credit circumstances groups historical experience taking also account economic conditions expenses doubtful trade receivables recognised within marketing distribution expenses trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience roche finance report roche group notes roche group consolidated financial statements cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash equivalents readily convertible known amounts cash subject insignificant risk changes fair value maturity three months less date acquisition provisions contingencies provisions recognised legal constructive obligation incurred probably lead outflow resources reliably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise discounted time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available financial instruments financial instruments classified following categories disclosed note availableforsale nonderivative financial assets either designated classified financial asset category availableforsale assets initially recorded subsequently carried fair value changes fair value recorded comprehensive income except impairments interest foreign exchange components investment derecognised cumulative gains losses equity reclassified financial income expense availableforsale assets mainly comprised marketable securities fair value hedging instruments derivative financial instruments used manage exposures foreign currency interest rate equity market credit risks derivative financial instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments changes fair value recorded financial income expense fair value designated nonderivative financial instruments designated fair value profit loss initial recognition designated fair value instruments initially recorded subsequently carried fair value changes fair value recorded income statement designated fair value instruments mainly comprised contingent consideration liabilities changes fair value recorded general administration within operating results loans receivables nonderivative financial assets fixed determinable payments quoted active market loans receivables initially recorded fair value subsequently carried amortised cost using effective interest rate method less impairment losses loans receivables mainly comprised accounts receivable cash cash equivalents financial liabilities nonderivative financial liabilities financial liabilities initially recorded fair value subsequently carried amortised cost using effective interest rate method financial liabilities mainly comprised debt trade payables financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership financial asset transferred financial liability derecognised contractual obligations discharged cancelled expire roche finance report notes roche group consolidated financial statements roche group impairment financial assets financial assets individually assessed possible impairment reporting date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty available forsale equity securities market value original cost market value original cost sustained sixmonth period considered impaired financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial assets impairment charge amount currently carried comprehensive income difference original cost fair value impairment loss reversed reversal related objectively event occurring impairment loss recognised debt securities measured amortised cost availableforsale reversal recognised income equity securities held availableforsale reversal recognised directly comprehensive income hedge accounting group uses derivatives manage exposures foreign currency interest rate equity market credit risks instruments used may include interest rate swaps crosscurrency swaps forwards contracts options group generally limits use hedge accounting certain significant transactions qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income expense cash flow hedge hedge exposure variability cash flows attributable particular risk associated recognised asset liability highly probable forecast transaction could affect profit loss hedging instrument recorded fair value effective portion hedge included comprehensive income ineffective portion reported financial income expense hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial item cumulative changes fair value hedging instrument recorded comprehensive income included initial carrying value nonfinancial item date recognition cash flow hedges cumulative changes fair value hedging instrument recorded comprehensive income included financial income expense forecasted transaction affects net income fair value hedge hedge exposure changes fair value recognised asset liability unrecognised firm commitment identified portion asset liability firm commitment attributable particular risk could affect profit loss hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income expense debt debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted foreseeable future roche finance report roche group notes roche group consolidated financial statements deferred tax assets liabilities recognised temporary differences tax bases assets liabilities carrying values deferred tax assets recognised extent probable future taxable profit available unused tax losses utilised current deferred tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred taxes determined based currently enacted tax rates applicable tax jurisdiction group operates equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments held groups potential conversion obligations may arise groups equity compensation plans changes accounting policies group adopted following new standards amendments standards including consequential amendments standards date initial application january investment entities amendments ifrs ifrs ias offsetting financial assets financial liabilities amendments ias recoverable amount disclosures nonfinancial assets amendments ias novation derivatives continuation hedge accounting amendments ias ifric levies material impact groups overall results financial position future new revised standards group currently assessing potential impacts various new revised standards interpretations mandatory january group yet applied based analysis date group anticipate material impact groups overall results financial position group also assessing new revised standards mandatory notably ifrs financial instruments ifrs revenues contracts customers subsequent events january swiss national bank announced discontinuing minimum exchange rate swiss francs per euro amounts reported annual financial statements reflect changes foreign exchange rates december since group uses swiss franc presentation currency consolidated financial statements weakening foreign currencies swiss franc negative currency translation impact groups consolidated results reported swiss francs date approval annual financial statements changes foreign exchange rates caused material foreign exchange transaction gains losses groups results groups foreign exchange risk management disclosed note currency translation sensitivity groups results movements foreign currency exchange rates included financial review pages roche finance report report roche management internal control financial reporting roche group report roche management internal control financial reporting report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reasonable assurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework version issued committee sponsoring organizations treadway commission coso based assessment management concluded system internal control financial reporting effective december statutory auditor kpmg ag audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa also issued report effectiveness groups system internal control financial reporting report set christoph franz alan hippe chairman board directors chief financial officer basel january roche finance report roche group report statutory auditor consolidated financial statements report statutory auditor consolidated financial statements report statutory auditor general meeting shareholders roche holding ltd basel statutory auditor audited accompanying consolidated financial statements roche holding ltd comprise income statement statement comprehensive income balance sheet statement cash flows statement changes equity notes pages year ended december board directors responsibility board directors responsible preparation consolidated financial statements accordance international financial reporting standards ifrs requirements swiss law responsibility includes designing implementing maintaining internal control system relevant preparation consolidated financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion consolidated financial statements based audit conducted audit accordance swiss law swiss auditing standards international standards auditing standards require plan perform audit obtain reasonable assurance whether consolidated financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures consolidated financial statements procedures selected depend auditors judgement including assessment risks material misstatement consolidated financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation consolidated financial statements order design audit procedures appropriate circumstances audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation consolidated financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion consolidated financial statements year ended december give true fair view financial position results operations cash flows accordance international financial reporting standards ifrs comply swiss law report legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation consolidated financial statements according instructions board directors recommend consolidated financial statements submitted approved kpmg ag ian starkey franois rouiller licensed audit expert auditor charge licensed audit expert basel january roche finance report report independent auditor internal control financial reporting roche group report independent auditor internal control financial reporting report independent auditor internal control financial reporting board directors roche holding ltd basel examined roche groups system internal control financial reporting december based criteria established internal control integrated framework version issued committee sponsoring organizations treadway commission coso board directors management roche holding ltd responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying report roche management internal control financial reporting responsibility express opinion companys internal control financial reporting based examination entitys internal control financial reporting process effected entitys board directors management personnel designed provide reasonable assurance regarding reliability financial statements prepared accordance international financial reporting standards ifrs includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets entity provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance applicable financial reporting framework provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition entitys assets could material effect entitys financial statements conducted examination accordance international standard assurance engagements isae standard requires plan perform examination obtain reasonable assurance whether effective internal control financial reporting maintained material respects examination included obtaining understanding internal control financial reporting testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe examination provides reasonable basis opinion inherent limitations internal control financial reporting including possibility management override controls misstatements due error fraud may occur detected also projections evaluation internal control financial reporting future periods subject risk internal control may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion roche group maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework version issued committee sponsoring organizations treadway commission coso also audited accordance swiss auditing standards international standards auditing consolidated financial statements roche holding ltd year ended december report dated january expressed unqualified opinion consolidated financial statements kpmg ag ian starkey franois rouiller licensed audit expert auditor charge licensed audit expert basel january roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied retrospectively dividend proposed board directors roche finance report multiyear overview supplementary information roche group multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied retrospectively dividend proposed board directors roche finance report roche group multiyear overview supplementary information sales division millions chf pharmaceuticals diagnostics total sales geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report multiyear overview supplementary information roche group additions property plant equipment division millions chf pharmaceuticals diagnostics corporate total additions property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report roche group multiyear overview supplementary information supplementary core results eps information groups basic diluted earnings per share given note annual financial statements allow transparent assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core results concept used internal management business based ifrs results following adjustments global restructuring plans see note excluded amortisation impairment intangible assets see note impairment goodwill see note excluded acquisition accounting onetime impacts alliance arrangements business combinations see financial review excluded discontinued operations currently none would excluded legal environmental expenses see financial review excluded global issues outside healthcare sector beyond groups control currently none would excluded material onetime treasury items major debt restructurings see note excluded pension plan settlements see note excluded tax benefit recorded ifrs respect equity compensation plans ecps varies according price underlying equity replaced normalised tax benefit ifrs expense multiplied applicable tax rate see note core results concept described october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm groups ifrs results including divisional breakdown reconciled core results tables calculation core eps also given tables additional commentary adjustment items given financial review roche finance report multiyear overview supplementary information roche group core results reconciliation millions chf alliances normali global intangibles business legal major debt pension sation restruc amorti intangibles combi environ restruc plan ecp tax ifrs turing sation impairment nations mental turing settlements benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results reconciliation millions chf alliances normali global intangibles business legal pension sation restruc amorti intangibles combi environ plan ecp tax ifrs turing sation impairment nations mental settlements benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests roche finance report roche group multiyear overview supplementary information divisional core results reconciliation millions chf alliances global intangibles business legal pension restruc amorti intangibles combi environ plan ifrs turing sation impairment nations mental settlements core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit divisional core results reconciliation millions chf alliances global intangibles business legal pension restruc amorti intangibles combi environ plan ifrs turing sation impairment nations mental settlements core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report multiyear overview supplementary information roche group core eps basic core net income attributable roche shareholders chf millions weighted average number shares nonvoting equity securities issue millions core earnings per share basic chf core eps diluted core net income attributable roche shareholders chf millions increase noncontrolling interests share core net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions core earnings per share diluted chf roche finance report roche group multiyear overview supplementary information supplementary operating free cash flow information divisional operating free cash flow information millions chf pharmaceuticals diagnostics corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible assets impairment reversal property plant equipment impairment goodwill impairment intangible assets total adjustments add back expenses equitysettled equity compensation plans net income expense provisions net gain loss disposals noncash working capital items deduct utilisation provisions proceeds disposals total operating profit cash adjustments ebitda core operating profit depreciation impairment property plant equipment core basis ebitda margin sales roche finance report multiyear overview supplementary information roche group supplementary balance sheet information net operating assets balance sheet reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury roche group property plant equipment goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets net operating assets balance sheet reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury roche group property plant equipment goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets roche finance report roche group roche securities roche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr sp index rebased eight roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july information tables restated change ratio adrs effective january change ratio adrs effective january change ratio adrs effective february roche finance report roche securities roche group number shares nonvoting equity securities number shares nominal value chf number nonvoting equity securities genussscheine nominal value total number shares nonvoting equity securities genussscheine held total issue data per share nonvoting equity security chf earnings basic earnings diluted core earnings basic core earnings diluted equity attributable roche shareholders dividend c stock price share b opening high low yearend stock price nonvoting equity security genussschein b opening high low yearend market capitalisation millions chf yearend key ratios yearend dividend yield shares dividend yield nonvoting equity securities genussscheine priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed six swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors ticker symbols share nonvoting equity security american depositary receipt adr six swiss exchange ro rog bloomberg ro sw rog vx rhhby us reuters ros rogvx rhhbypk roche finance report roche holding ltd basel financial statements notes financial statements summary significant accounting policies ignificant shareholders e quity r isk management contingent liabilities board executive shareholdings appropriation available earnings report statutory auditor financial statements financial statements roche holding ltd basel financial statements income statement millions chf year ended december income income participations interest income loans group companies interest investment income guarantee fee income group companies income total income expenses financial expenses administration expenses expenses total expenses profit taxes taxes net income roche finance report roche holding ltd basel financial statements balance sheet millions chf december december noncurrent assets participations longterm loans group companies total noncurrent assets current assets accounts receivable group companies shortterm loans group companies accounts receivable marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm legal reserve general legal reserve reserve equity instruments free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions total noncurrent liabilities current liabilities accounts payable group companies unrealised foreign currency gains liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value roche finance report notes financial statements roche holding ltd basel notes financial statements summary significant accounting policies basis preparation financial statements roche holding ltd basel prepared accordance provisions swiss law participations major participations company listed note roche group annual financial statements valuation methods translation foreign currencies marketable securities equity instruments reported lower cost market value assets including participations reported cost less appropriate writedowns assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except participations translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred taxes tax charge includes corporate income capital taxes equity share capital previous year share capital amounts million swiss francs share capital consists bearer shares nominal value swiss franc included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value share capital participation certificates equity instruments company purchase roche shares million roche shares purchase price swiss francs per share sold roche shares roche shares average sales price swiss francs per share swiss francs per share net gain million swiss francs net gain million swiss francs dividend income amounted million swiss francs nil december remaining roche shares roche shares net book value million swiss francs million swiss francs included marketable securities roche finance report roche holding ltd basel notes financial statements movement recognised amounts millions chf share legal free special available total capital reserve reserve reserve earnings equity january net income dividends transfer free reserve december net income dividends reserve equity instruments december net income dividends reserve equity instruments december contingent liabilities guarantees company issued guarantees certain bonds notes commercial paper credit facilities group companies nominal amount outstanding december billion swiss francs billion swiss francs described note roche group annual financial statements significant shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting march information available company controlling shareholders december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool december based information supplied group shares shares owned novartis ltd basel including affiliates thereof participation roche finance report notes financial statements roche holding ltd basel risk management detailed disclosures regarding risk management required swiss law included note roche group annual financial statements board executive shareholdings board directors directors mr andr hoffmann dr andreas oeri certain members founders families closely associated belong shareholder group pooled voting rights end group held shares issued shares detailed information group given note addition end year members board directors persons closely associated held shares nonvoting equity securities genussscheine shown table mr arthur levinson resigned september annual general meeting march dr franz humer mr william burns stand reelection mr bernard poussot professor richard lifton nominated election new members board directors agm march shareholdings members board directors nonvoting equity securities shares genussscheine c franz fb humer na na b hoffmann p baschera ji bell p bulcke wm burns na na b julius ad levinson na na oeri schwan b c pr voser b weder di mauro total include shares held shareholder group pooled voting rights b equity compensation awards roche option plan ssars rsus roche performance share plan see c dr schwan appointed board directors march shareholdings disclosed tables member corporate executive committee roche finance report roche holding ltd basel notes financial statements corporate executive committee members corporate executive committee persons closely associated held shares nonvoting equity securities shown table shareholdings members corporate executive committee nonvoting equity securities shares genussscheine schwan ayyoubi r diggelmann hippe ga keller b oday total equity compensation awards roche option plan ssars rsus roche performance share plan b close relatives dr keller held roche shares roche shares december members corporate executive committee held roche option plan awards rops stocksettled stock appreciation rights ssars shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages rops ssars awards held december year issue total schwan ayyoubi r diggelmann hippe ga keller oday total cec strike price chf expiry date mar mar mar feb feb feb july december members corporate executive committee held restricted stock units rsus shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages rsu awards allocated individually remuneration committees discretion vested recipient three years thereafter resulting nonvoting equity securities may remain blocked ten years rsu awards held december year issue total schwan ayyoubi r diggelmann hippe ga keller oday total cec roche finance report notes financial statements roche holding ltd basel december members corporate executive committee shown table held psp awards psp performance cycles terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages award result zero two nonvoting equity securities value adjustment depending upon achievement performance targets discretion board directors end cycle performance targets achieved accordingly participants receive originally targeted nonvoting equity securities total target number awards outstanding performance cycles december shown table roche performance share plan awards held december psp psp schwan ayyoubi r diggelmann hippe ga keller oday total cec allocation date feb feb december mr william burns members corporate executive committee time held total stock settled stock appreciation rights restricted stock units outstanding total awards granted roche performance share plan roche finance report roche holding ltd basel appropriation available earnings appropriation available earnings proposals annual general meeting chf available earnings balance brought forward previous year net profit year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year transfer free reserve total appropriation available earnings carried forward account roche finance report report statutory auditor financial statements roche holding ltd basel report statutory auditor financial statements report statutory auditor general meeting shareholders roche holding ltd basel statutory auditor audited accompanying financial statements roche holding ltd comprise income statement balance sheet notes pages year ended december board directors responsibility board directors responsible preparation financial statements accordance requirements swiss law companys articles incorporation responsibility includes designing implementing maintaining internal control system relevant preparation financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion financial statements based audit conducted audit accordance swiss law swiss auditing standards standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures financial statements procedures selected depend auditors judgement including assessment risks material misstatement financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation financial statements order design audit procedures appropriate circumstances purpose expressing opinion effectiveness entitys internal control system audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion financial statements year ended december comply swiss law companys articles incorporation report legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation financial statements according instructions board directors confirm proposed appropriation available earnings complies swiss law companys articles incorporation recommend financial statements submitted approved kpmg ag ian starkey franois rouiller licensed audit expert auditor charge licensed audit expert basel january roche finance report published cautionary statement regarding forwardlooking statements f hoffmannla roche ltd annual report contains certain forwardlooking statements basel switzerland forwardlooking statements may identi fied words believes tel expects anticipates projects intends seeks estimates fax future similar expressions discussion among things strategy goals plans intentions various factors may cause actual results differ materially future reflected forward media office looking statements contained annual report among others group communications pricing product initiatives competitors legislative basel switzerland regulatory developments economic conditions delay inability tel obtaining regulatory approvals bringing products market fax fluctuations currency exchange rates general financial market conditions uncertainties discovery development marketing new products new uses existing products including without investor relations limitation negative results clinical trials research projects basel switzerland unexpected side effects pipeline marketed products increased tel government pricing pressures interruptions production loss fax inability obtain adequate protection intellectual property rights litigation loss key executives employees adverse publicity news coverage website wwwrochecom statement regarding earnings per share growth profit forecast interpreted mean roches earnings earnings per share subsequent period necessarily order publications match exceed historical published earnings earnings per share tel roche fax email baselwebmasterrochecom trademarks mentioned enjoy legal protection roche finance report published german english case next annual general meeting doubt differences interpretation english version shall prevail march german text printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel group communicationsfhoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche finance report finance report